<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="inhibit">
            <roleset id="inhibit.01" name="" wordnet="2">
                <roles>
                    <role n="0" descr="agent&#x0A;" />
                    <role n="1" descr="the entity being inhibited by agent to get binding&#x0A;" />
                    <role n="2" descr="the action or property being inhibited&#x0A;" />
                </roles>
                <example src="EGRAM" no="0">
                    <text>A0 is able to completely inhibit ligand that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">ligand</arg>
                </example>
                <example src="EGRAM" no="1">
                    <text>A2 can be inhibited by nitric oxide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="EGRAM" no="2">
                    <text>CRP-cAMP is able to strongly inhibit sigma (54)-gnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="EGRAM" no="3">
                    <text>For example, phosphatase associated with other protein is inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="EGRAM" no="4">
                    <text>For example, phosphatase may have been associated with other protein and has therefore been inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="EGRAM" no="5">
                    <text>For example, phosphatease associated with other protein may have been inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="EGRAM" no="6">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW is able to inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="EGRAM" no="7">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW may inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="EGRAM" no="8">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadX-dependent activation will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="9">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadX-dependent was inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="EGRAM" no="10">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadX-dependent will be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="EGRAM" no="11">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GadX-dependent activation is observed to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="EGRAM" no="12">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="EGRAM" no="13">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the CRP-cAMP complex will inhibited the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="EGRAM" no="14">
                    <text>In addition, A0 inhibited the A2 connection (Lrp/PapI) near the GATC1028 site and altered the Lrp connection to the GATC1130 site.</text>
                </example>
                <example src="EGRAM" no="15">
                    <text>In addition, A0 inhibits Lrp/PapI binding near the GATC 1028 site and alters Lrp binding to the GATC 1130 site.</text>
                </example>
                <example src="EGRAM" no="16">
                    <text>In addition, methylation of prey may have inhibited Lrp/PapI binding near the GATC1028 site and alters Lrp binding to the GATC1130 site.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="EGRAM" no="17">
                    <text>In this work, we found that reduced regulation of Stat4, Stat5 and Stat6 is inhibited by proteasome inhibitors MG132 and lactacistin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="EGRAM" no="18">
                    <text>N-terminal SH3 domain (SH3A), unlike other intersectin SH3 inhibited or several endocrine proteins, specifically inhibited intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="EGRAM" no="19">
                    <text>N-terminal domain H3 (HH3A), unlike other intersection HH3 domains or several endocytic proteins, specifically inhibits intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="EGRAM" no="20">
                    <text>NK cell-mediated cytotoxicity was inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="21">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="22">
                    <text>Natural killer cells (NK) express cell surface receptors for immunoglobulin and type C lectins superfamilies that inhibited class I peptides of the greater compatibility complex (MHC) and inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="EGRAM" no="23">
                    <text>Roipram can inhibit multiple PDE4-specific phosphodiesterase isoforms encoded by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="EGRAM" no="24">
                    <text>The intrigue is that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, will selectively inhibit late events of clathrin-coated vesicles formation involving membrane fission, SH3A was only in its ability to block previous stages</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="EGRAM" no="25">
                    <text>The intrigue is that the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endocile proteins endophyline I, ampphiphisine II and symphpine I), selectively inhibit late clathrin-coated vesicle formation events inhibited membrane fission, the SH3A was only in its ability to block earlier stages (</text>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="EGRAM" no="26">
                    <text>Transient overexpression in body cells has inhibit that a hot protein kinase inhibitor is produced by mitochondrial DNA of the protein kinase, and protein extracts from transfected body cells inhibits both alpha isoforms as C beta of the PKA catalytic subunit with equal efficacy.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="EGRAM" no="27">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts from transfected cells.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="EGRAM" no="28">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that protein extracts from transcent body cells is capable of inhibiting both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="29">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that protein extracts from transfect body cells may have inhibited both the isoforms C alpha and beta C of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="30">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and both the isoforms C alpha and C beta of the catalytic subunit PKA will be inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="EGRAM" no="31">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="EGRAM" no="32">
                    <text>binding is a dependent and saturable concentration and is observed to be totally inhibited with DTA of 10 mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="EGRAM" no="33">
                    <text>depending on sigma (54)-gnAp2 is strongly inhibited by CRP-cAMP by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="EGRAM" no="34">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in T-lycemic cells transfected, wil is also inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="EGRAM" no="35">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected Jurkat T-cells is also inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="EGRAM" no="36">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected Jurkat T-cells was also inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="EGRAM" no="37">
                    <text>intermediate events leading to the formation of clathrin coated wells are observed to be inhibited by A0 (the N-terminal domain SH3 (SH3A) which is different from other intersectin SH3 domains or various endocite proteins.</text>
                    <arg n="2">intermediate events leading to the formation of clathrin coated wells</arg>
                </example>
                <example src="EGRAM" no="38">
                    <text>intermediate events that lead to the formation of clathrin-coated wells can be inhibited by A0 (N-terminal domain SH3 (SH3A), which is different from other domains of intersectin SH3 or several endocrine proteins.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="EGRAM" no="39">
                    <text>intermediate events that lead to the formation of clathrin-coated wells will be inhibited by A0 (N-terminal domain SH3 (SH3A), which is different from other domains of intersectin SH3 or several endocrine proteins.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="EGRAM" no="40">
                    <text>late events of clathrin-coated vesicles formation was inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="EGRAM" no="41">
                    <text>ligand is concentration-dependent and saturable and is able to be fully inhibited with 10 mM EDTA , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="EGRAM" no="42">
                    <text>ligand is concentration-dependent and saturable and it is inhibited that 10mM EDTA is totally inhibited, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="EGRAM" no="43">
                    <text>nitric oxide (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="44">
                    <text>nitric oxide (NO) inhibiting platelet function activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="45">
                    <text>nitric oxide inhibited platelet function activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="46">
                    <text>nitric oxide inhibited platquet function activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="EGRAM" no="47">
                    <text>nitric oxide inhibited the soluble isoform of guanilate cyclase in platelets and inhibited platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="EGRAM" no="48">
                    <text>nitric oxide inhibited the soluble isoform of guanilate cyclase in platelets and inhibits platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="EGRAM" no="49">
                    <text>platelet function can be inhibited by nitric oxide which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="EGRAM" no="50">
                    <text>sigma (54) - glnAp2 was strongly inhibited by CRP-cAMP 21 times.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="EGRAM" no="51">
                    <text>sigma (54)-dependent glnAp2 has been strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="52">
                    <text>sigma (54)-dependent glnAp2 is observed to be strongly inhibited by CRP-cAMP, by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="EGRAM" no="53">
                    <text>sigma (54)-gnAp2 is strongly inhibited by CRP-cAMP by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="EGRAM" no="54">
                    <text>the function of phosphateases and localization will be inhibited if phosphatease is associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="1">
                    <text>10 mM EDTA can fully inhibit ligand that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="2">
                    <text>10 mM EDTA can totally inhibit ligand that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="3">
                    <text>10 mM EDTA fully inhibiting concentration-dependent ligand and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="4">
                    <text>10 mM EDTA may also have inhibited ligand in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="5">
                    <text>A0 inhibits negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="6">
                    <text>A2 can be inhibited by Roipram that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="7">
                    <text>A2 can be inhibited by protein extracts of the transfected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="8">
                    <text>A2 can be inhibited by protein extracts of transfected cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="9">
                    <text>A2 is inhibited by protein extracts of infected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="10">
                    <text>A2 may have been inhibited by protein extracts of transfected cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="11">
                    <text>AAM-3 expression also has the ability to inhibit functional activation of an HIV plasmid reporter for p49/p65 in transient transfected T-cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="12">
                    <text>AAM-3 expression has also inhibited functional activation of an HIV plasmid reporter for p49/p65 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="13">
                    <text>AAM-3 expression may also have inhibited functional activation of an HIV plasmid reporter for p49/p65 in T cells affected by jurkat.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="14">
                    <text>CRP-cAMP can strongly inhibit sigma (54)-gnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="15">
                    <text>CRP-cAMP complex (NO) inhibiting gnAp2 promoting activity activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="16">
                    <text>CRP-cAMP complex also inhibited activity promotionAp2 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="17">
                    <text>CRP-cAMP complex also inhibits activity promotionAp2 in transient transfected T-cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="18">
                    <text>CRP-cAMP complex can fully inhibit activity promotionAp2 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="19">
                    <text>CRP-cAMP complex can totally inhibit activity promotionAp2 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="20">
                    <text>CRP-cAMP complex can totally inhibit gnAp2 promoting activity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="21">
                    <text>CRP-cAMP complex co-expression also has the ability to inhibit activity promotionAp2 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="22">
                    <text>CRP-cAMP complex has also inhibited gnAp2 promoting activity in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="23">
                    <text>CRP-cAMP complex may also have inhibited activity promotionAp2 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="24">
                    <text>CRP-cAMP has the ability to strongly inhibit sigma (54) - glnAp2 by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="25">
                    <text>CRP-cAMP has the ability to strongly inhibit sigma (54)-gnAp2 by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="26">
                    <text>CRP-cAMP inhibits sigma (54) - glnAp2 codified by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="27">
                    <text>CRP-cAMP is able to inhibit sigma (54) - glnAp2 coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="28">
                    <text>CRP-cAMP may inhibit sigma (54)-gnAp2 coded by PDE4C.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="29">
                    <text>CRP-cAMP strongly inhibited sigma (54) - glnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="30">
                    <text>CRP-cAMP strongly inhibited sigma (54)-dependent glnAp2 by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="31">
                    <text>CRP-cAMP strongly inhibits sigma (54)-dependent glnAp2 by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="32">
                    <text>DTA of 10 mM (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="33">
                    <text>DTA of 10 mM (NO) inhibiting ligand activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="34">
                    <text>DTA of 10 mM (NO) inhibiting ligand activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="35">
                    <text>DTA of 10 mM activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="36">
                    <text>DTA of 10 mM also inhibits binding in transient transfected T-cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="37">
                    <text>DTA of 10 mM also inhibits binding in transiently transfected T-leukemia cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="38">
                    <text>DTA of 10 mM can totally inhibit binding that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="39">
                    <text>DTA of 10 mM may also have inhibited binding in T cells affected by jurkat.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="40">
                    <text>EDTA 10mM (NO) inhibiting binding activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="41">
                    <text>EDTA 10mM activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="42">
                    <text>EDTA 10mM co-expression also has the ability to inhibit ligand in T-leukemia transnetly affected cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="43">
                    <text>EDTA 10mM fully inhibiting concentration-dependent binding and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="44">
                    <text>EDTA 10mM inhibited binding activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="45">
                    <text>EDTA 10mM inhibited ligand activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="46">
                    <text>EDTA 10mM may have completely inhibited ligand that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="47">
                    <text>EDTA of 10 mM also inhibits ligand in transient transfected T-cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="48">
                    <text>EDTA of 10 mM fully inhibiting concentration-dependent ligand and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="49">
                    <text>EDTA of 10 mM inhibits ligand activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="50">
                    <text>For example, P associated with This synthetic peptide was inhibited in its C3b binding.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="PERMUTATE" no="51">
                    <text>For example, P associated with this synthetic peptide can be inhibited in its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="52">
                    <text>For example, P associated with this synthetic peptide may have been inhibited in its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="53">
                    <text>For example, P is associated with this synthetic peptide and is therefore inhibited in its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="PERMUTATE" no="54">
                    <text>For example, phosphatase associated with another protein can be inhibited in the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="55">
                    <text>For example, phosphatase associated with another protein may be inhibited in the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="56">
                    <text>For example, phosphatase associated with other protein is inhibited in function and location of phosphateases.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="57">
                    <text>For example, phosphatase associated with other protein may be inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="58">
                    <text>For example, phosphatase associated with other protein was inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="59">
                    <text>For example, phosphatase is associated with other protein and is therefore inhibited in its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="60">
                    <text>For example, phosphatease associated with other proteins can be inhibited in its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="61">
                    <text>For example, phosphatease associated with other proteins is inhibited in its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="62">
                    <text>For example, phosphatease is associated with other protein and is therefore inhibited in the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="63">
                    <text>For example, phosphatease may have been associated with other proteins and has therefore been inhibited in its function or location.</text>
                    <arg n="0">other proteins</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="64">
                    <text>GM132 proteasome inhibitors and laactacytin (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="65">
                    <text>GM132 proteasome inhibitors and laactacytin also inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated in transfected T-leukemia cells transfected.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="66">
                    <text>GM132 proteasome inhibitors and laactacytin also inhibits negative regulation of Stat4, Stat5 and Stat6 phosphorylated in transiently transfected T-leukemia cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="67">
                    <text>GM132 proteasome inhibitors and laactacytin inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="68">
                    <text>GM132 proteasome inhibitors and laactacytin inhibits negative regulation of Stat4, Stat5 and Stat6 phosphorylated activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="69">
                    <text>GadW (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="70">
                    <text>GadW also has the ability to inhibit GadX-dependent in transient transfected T-cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="71">
                    <text>GadW also has the ability to inhibit depending on GadX in transient transfected T-cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="72">
                    <text>GadW also inhibited GadX-dependent in transfected T-leukemia cells transfected.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="73">
                    <text>GadW also inhibits depending on GadX in transiently transfected T-leukemia cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="74">
                    <text>GadW can fully inhibit GadX-dependent activation that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="75">
                    <text>GadW can totally inhibit depending on GadX that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="76">
                    <text>GadW co-expression also has the ability to inhibit depending on GadX in T-leukemia transnetly affected cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="77">
                    <text>GadW fully inhibiting concentration-dependent depending on GadX and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="78">
                    <text>GadW inhibits GadX-dependent activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="79">
                    <text>GadW may have completely inhibited GadX-dependent activation which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="80">
                    <text>GadW may have completely inhibited GadX-dependent that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="81">
                    <text>GadW may have completely inhibited GadX-dependent which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="82">
                    <text>GadW may have completely inhibited depending on GadX which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="83">
                    <text>GadW may have inhibited GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="84">
                    <text>GadW may have inhibited depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="85">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while CRP-cAMP complex inhibits activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="86">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while CRP-cAMP complex is able to inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="87">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while CRP-cAMP complex may have inhibited gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="88">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while DTA of 10 mM inhibited ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="89">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while DTA of 10 mM inhibits ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="90">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while DTA of 10 mM is able to inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="91">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while DTA of 10 mM is able to inhibit ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="92">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA 10mM inhibits binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="93">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA 10mM is able to inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="94">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA 10mM may have inhibited binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="95">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA 10mM may inhibit binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="96">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA 10mM may inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="97">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while EDTA of 10 mM inhibits ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="98">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW inhibits GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="99">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW is able to inhibit depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="100">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while GadW may have inhibited depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="101">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAD-3 co-expression is able to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="102">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAD-3 expression inhibits functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="103">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAD-3 expression is able to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="104">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while MAR expression may inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="105">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while Mad-3 co-expression inhibits functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="106">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity is inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="107">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while NK-mediated cytotoxicity is inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="108">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I may inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="109">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while activity promotionAp2 was inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="110">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while an inhibitor of the MG132 protein and lactacittine inhibited regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="111">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while an inhibitor of the MG132 protein and lactacittine inhibits regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="112">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while an inhibitor of the MG132 protein and lactacittine is able to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="113">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while an inhibitor of the MG132 protein and lactacittine may have inhibited regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="114">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while binding is inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="115">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while binding was inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="116">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while binding will be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="117">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and C-type lectin superfamilies inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="118">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="119">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin superfamilies and type C lectins may have inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="120">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for the superfamilies of immunoglobulin and type C lectin may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="121">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for the superfamilies of immunoglobulin and type C lectin may inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="122">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors of immunoglobulin and C-type superfamilies is able to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="123">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while chloramphenicol is able to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="124">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while co-expression of AAM-3 may have inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="125">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while co-expression of AAM-3 may inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="126">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while descendant regulation of phosphorylation state, state5 and state6 was inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="127">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="128">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="129">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="130">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="131">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV plasmid reporter for p49/p65 is inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="132">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV plasmid reporter for p49/p65 will be inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="133">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV reporter plasmid by p49/p65 is inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="134">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="135">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="136">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while gnAp2 promoting activity was inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="137">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while inhibitors of the MG132 proteasome and lactacyttin inhibits the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="138">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="139">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="140">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand is inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="141">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand is inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="142">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while mainly the inhibitors of the MG132 proteasome and lactacittina may have inhibited descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="143">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while negative regulation of Stat4, Stat5 and Stat6 phosphorylated is inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="144">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while platquet function will be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="145">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while primary proteasome inhibitors MG132 and lactacyttin is able to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="146">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while proteasome inhibitors MG132 and lactacistin is able to inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="147">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while protein synthesis will be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="148">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the CRP-cAMP complex inhibits the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="149">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibited late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="150">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="151">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while AAM-3 expression inhibited functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="152">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while DTA of 10 mM inhibited ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="153">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while DTA of 10 mM is observed to inhibit binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="154">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while GadW inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="155">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while MAD-3 co-expression inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="156">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while MAD-3 expression inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="157">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while Mad-3 inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="158">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while NK cell-mediated cytotoxicity is observed to be inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="159">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while NK-mediated cytotoxicity is observed to be inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="160">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while an inhibitor of the MG132 protein and lactacittine is observed to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="161">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="162">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors of immunoglobulin and Clectin superfamilies inhibited NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="163">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cellular surface receptors for immunoglobulin and C-type lectin inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="164">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while chloramphenicol inhibited protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="165">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while functional activation of an HIV plasmid reporter for p49/p65 is observed to be inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="166">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while functional activation of an HIV reporter plasmid by p49/p65 is observed to be inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="167">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while late clathrin-coated vesicle formation events is observed to be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="168">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while late events of clathrin-coated vesicles formation is observed to be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="169">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while ligand is observed to be inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="170">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while mainly the inhibitors of the MG132 proteasome and lactacittina inhibited descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="171">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while nitric oxide inhibits platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="172">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while nitric oxide is observed to inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="173">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while proteasome inhibitors MG132 and lactacistin inhibits reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="174">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while protein synthesis is observed to be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="175">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while reduced regulation of Stat4, Stat5 and Stat6 is observed to be inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="176">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibits late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="177">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I is observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="178">
                    <text>GadX-dependent activation can be inhibited by GadW which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="179">
                    <text>GadX-dependent activation is a dependent and saturable concentration and has been totally inhibited with GadW, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="180">
                    <text>GadX-dependent activation is able to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="181">
                    <text>GadX-dependent in T-lycemic cells transfected, wil is also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="182">
                    <text>GadX-dependent is a dependent and saturable concentration and can be fully inhibited with GadW, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="183">
                    <text>GadX-dependent is a dependent and saturable concentration and has been totally inhibited with GadW, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="184">
                    <text>GadX-dependent is inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="185">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA can inhibit ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="186">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA inhibited ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="187">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex will inhibited activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="188">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM inhibited binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="189">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM will inhibited ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="190">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GM132 proteasome inhibitors and laactacytin will inhibited negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="191">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW has inhibited GadX-dependent activation.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="192">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadW has the ability to inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="193">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that GadX-dependent activation has been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="194">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAD-3 co-expression inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="195">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that MAD-3 co-expression will inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="196">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Mad-3 co-expression will inhibited functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="197">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK cell-mediated cytotoxicity can be inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="198">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK cell-mediated cytotoxicity can be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="199">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="200">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity will be inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="201">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Roipram inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="202">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Roipram inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="203">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="204">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I will inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="205">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that activity promotionAp2 is inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="206">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that an inhibitor of the MG132 protein and lactacittine has the ability to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="207">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that binding has been inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="208">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and C-type lectin superfamilies has inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="209">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and C-type lectin superfamilies will inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="210">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins has the ability to inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="211">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins will inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="212">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and C-type superfamilies can inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="213">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cellular surface receptors for immunoglobulin and C-type lectin will inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="214">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that chloramphenicol has the ability to inhibit protein synthesis.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="215">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that co-expression of AAM-3 has inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="216">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="217">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that descending regulation of the phosphorylation status, state5 and state6 will be inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="218">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="219">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="220">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 is inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="221">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="222">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that inhibitors of the MG132 proteasome and lactacyttin inhibited the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="223">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events can be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="224">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="225">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="226">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late events of clathrin-coated vesicles formation has been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="227">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand can be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="228">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand can be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="229">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand has been inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="230">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that mainly the inhibitors of the MG132 proteasome and lactacittina inhibited descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="231">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that mainly the inhibitors of the MG132 proteasome and lactacittina will inhibited descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="232">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that negative regulation of Stat4, Stat5 and Stat6 phosphorylated can be inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="233">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that negative regulation of Stat4, Stat5 and Stat6 phosphorylated has been inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="234">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide has the ability to inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="235">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nitric oxide inhibited platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="236">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that platquet function will be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="237">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacitstin has the ability to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="238">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of the transfected body cells can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="239">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts of transfected cells inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="240">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein synthesis has been inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="241">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that regulation of phosphorylated status, stage 5 and stage 6 has been inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="242">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I can inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="243">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I will inhibited late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="244">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I can inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="245">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I has the ability to inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="246">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="247">
                    <text>Here, we have found that GadX-dependent has been inhibited by GadW, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="248">
                    <text>Here, we have found that NK cell-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="249">
                    <text>Here, we have found that NK cell-mediated cytotoxicity has been inhibited by cell surface receptors of immunoglobulin and C-type superfamilies, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="250">
                    <text>Here, we have found that NK-mediated cytotoxicity will be inhibited by cellular surface receptors for immunoglobulin and C-type lectin, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="251">
                    <text>Here, we have found that binding will be inhibited by EDTA 10mM, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="252">
                    <text>Here, we have found that descendant regulation of phosphorylation state, state5 and state6 will be inhibited by primary proteasome inhibitors MG132 and lactacyttin, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="253">
                    <text>Here, we have found that functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by MAR expression, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="254">
                    <text>Here, we have found that functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by Mad-3, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="255">
                    <text>Here, we have found that functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by co-expression of AAM-3, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="256">
                    <text>Here, we have found that functional activation of an HIV plasmid reporter for p49/p65 has been inhibited by AAM-3 expression, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="257">
                    <text>Here, we have found that functional activation of an HIV reporter plasmid by p49/p65 has been inhibited by Mad-3, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="258">
                    <text>Here, we have found that gnAp2 promoting activity has been inhibited by CRP-cAMP complex, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="259">
                    <text>Here, we have found that late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="260">
                    <text>Here, we have found that late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="261">
                    <text>Here, we have found that late events of clathrin-coated vesicles formation has been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="262">
                    <text>Here, we have found that ligand has been inhibited by DTA of 10 mM, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="263">
                    <text>Here, we have found that ligand is inhibited by DTA of 10 mM, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="264">
                    <text>Here, we have found that negative regulation of Stat4, Stat5 and Stat6 phosphorylated will be inhibited by GM132 proteasome inhibitors and laactacytin, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="265">
                    <text>Here, we have found that platelet function has been inhibited by nitric oxide, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="266">
                    <text>Here, we have found that platquet function is inhibited by nitric oxide, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="267">
                    <text>Here, we have found that protein synthesis has been inhibited by chloramphenicol, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="268">
                    <text>Here, we have found that the glnAp2 promoter activity will be inhibited by the CRP-cAMP complex, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="269">
                    <text>Here, we have found that the regulation of phosphorylated state, state5 and state6 has been inhibited by a proteasome MG132 inhibitor and lactacitstin, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="270">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that AAM-3 expression is able to inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="271">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that CRP-cAMP complex has the ability to inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="272">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA 10mM has the ability to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="273">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA 10mM is able to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="274">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA 10mM is observed to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="275">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GM132 proteasome inhibitors and laactacytin is observed to inhibit negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="276">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW has the ability to inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="277">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadW is able to inhibit GadX-dependent.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="278">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that GadX-dependent activation is able to be inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="279">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that MAD-3 co-expression has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="280">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that Mad-3 co-expression has the ability to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="281">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="282">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I is observed to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="283">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that activity promotionAp2 has been inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="284">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that an inhibitor of the MG132 protein and lactacittine is able to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="285">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding is inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="286">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin and C-type lectin superfamilies is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="287">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and type C lectins has the ability to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="288">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for the superfamilies of immunoglobulin and type C lectin is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="289">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that depending on GadX has been inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="290">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that descendant regulation of phosphorylation state, state5 and state6 is able to be inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="291">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="292">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 is inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="293">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="294">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that inhibitors of the MG132 proteasome and lactacyttin is observed to inhibit the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="295">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="296">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="297">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand has been inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="298">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand has been inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="299">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand is able to be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="300">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand is able to be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="301">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that ligand is inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="302">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that mainly the inhibitors of the MG132 proteasome and lactacittina is able to inhibit descending regulation of the phosphorylation status, state5 and state6.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="303">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that nitric oxide is able to inhibit platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="304">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that nitric oxide is able to inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="305">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that primary proteasome inhibitors MG132 and lactacyttin is able to inhibit descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="306">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that protein synthesis is able to be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="307">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that reduced regulation of Stat4, Stat5 and Stat6 has been inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="308">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that regulation of phosphorylated status, stage 5 and stage 6 is able to be inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="309">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that the regulation of phosphorylated state, state5 and state6 is able to be inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="310">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that AAM-3 expression inhibits functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="311">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that AAM-3 expression is observed to inhibit functional activation of an HIV plasmid reporter for p49/p65.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="312">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that CRP-cAMP complex is observed to inhibit activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="313">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that DTA of 10 mM inhibited binding.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="314">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM inhibited binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="315">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that EDTA 10mM is observed to inhibit ligand.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="316">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM inhibited ligand.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="317">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that MAD-3 co-expression inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="318">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that Mad-3 inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="319">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that Mad-3 inhibits functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="320">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="321">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I is observed to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="322">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that a proteasome MG132 inhibitor and lactacitstin inhibited the regulation of phosphorylated state, state5 and state6.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="323">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that an inhibitor of the MG132 protein and lactacittine is observed to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="324">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and C-type lectin superfamilies is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="325">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin superfamilies and C-type lectins inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="326">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors of immunoglobulin and Clectin superfamilies inhibits NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="327">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that proteasome inhibitors MG132 and lactacistin is observed to inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="328">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I is observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="329">
                    <text>In this study, we found that GadX-dependent activation will be inhibited by GadW, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="330">
                    <text>In this study, we found that depending on GadX will be inhibited by GadW, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="331">
                    <text>In this study, we found that negative regulation of Stat4, Stat5 and Stat6 phosphorylated will be inhibited by GM132 proteasome inhibitors and laactacytin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="332">
                    <text>In this study, we found that regulation of phosphorylated status, stage 5 and stage 6 will be inhibited by an inhibitor of the MG132 protein and lactacittine, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="333">
                    <text>In this study, we found that the regulation of phosphorylated state, state5 and state6 will be inhibited by a proteasome MG132 inhibitor and lactacitstin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="334">
                    <text>In this work, we found that GadX-dependent activation is inhibited by GadW, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="335">
                    <text>In this work, we found that GadX-dependent activation was inhibited by GadW, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="336">
                    <text>In this work, we found that GadX-dependent activation was inhibited by GadW, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="337">
                    <text>In this work, we found that NK cell-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="338">
                    <text>In this work, we found that NK cell-mediated cytotoxicity was inhibited by cell surface receptors of immunoglobulin and C-type superfamilies, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="339">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="340">
                    <text>In this work, we found that NK-mediated cytotoxicity was inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="341">
                    <text>In this work, we found that binding was inhibited by DTA of 10 mM, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="342">
                    <text>In this work, we found that cytotoxicity mediated by NK cells was inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="343">
                    <text>In this work, we found that cytotoxicity mediated by NK cells was inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="344">
                    <text>In this work, we found that descendant regulation of phosphorylation state, state5 and state6 is inhibited by primary proteasome inhibitors MG132 and lactacitstin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="345">
                    <text>In this work, we found that functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by co-expression of AAM-3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="346">
                    <text>In this work, we found that functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAR expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="347">
                    <text>In this work, we found that functional activation of an HIV plasmid reporter for p49/p65 was inhibited by AAM-3 expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="348">
                    <text>In this work, we found that functional activation of an HIV reporter plasmid by p49/p65 is inhibited by MAD-3 expression, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="349">
                    <text>In this work, we found that gnAp2 promoting activity was inhibited by CRP-cAMP complex, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="350">
                    <text>In this work, we found that ligand is inhibited by 10 mM EDTA, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="351">
                    <text>In this work, we found that negative regulation of Stat4, Stat5 and Stat6 phosphorylated is inhibited by GM132 proteasome inhibitors and laactacytin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="352">
                    <text>In this work, we found that platelet function was inhibited by nitric oxide, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="353">
                    <text>In this work, we found that reduced regulation of Stat4, Stat5 and Stat6 was inhibited by proteasome inhibitors MG132 and lactacistin, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="354">
                    <text>In this work, we found that the glnAp2 promoter activity was inhibited by the CRP-cAMP complex, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="355">
                    <text>In this work, we found that the regulation of the phosphorylated state, Stat5 and Stat6 was inhibited by inhibitors of the MG132 proteasome and lactacyttin, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="356">
                    <text>MAD-3 co-expression (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="357">
                    <text>MAD-3 co-expression (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="358">
                    <text>MAD-3 co-expression fully inhibiting concentration-dependent functional activation of a plasmid HIV reporter by p49/ p65 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="359">
                    <text>MAD-3 co-expression has also inhibited functional activation of a plasmid HIV reporter by p49/ p65 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="360">
                    <text>MAD-3 expression (NO) inhibiting functional activation of an HIV reporter plasmid by p49/p65 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="361">
                    <text>MAD-3 expression also inhibits functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="362">
                    <text>MAD-3 expression inhibited functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="363">
                    <text>MAD-3 expression may have completely inhibited functional activation of an HIV reporter plasmid by p49/p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="364">
                    <text>MAD-3 expression may have completely inhibited functional activation of an HIV reporter plasmid by p49/p65 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="365">
                    <text>MAR expression (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="366">
                    <text>MAR expression (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="367">
                    <text>MAR expression has also inhibited functional activation of a plasmid HIV reporter by p49/ p65 in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="368">
                    <text>MAR expression inhibited functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="369">
                    <text>MAR expression may also have inhibited functional activation of a plasmid HIV reporter by p49/ p65 in T cells affected by jurkat.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="370">
                    <text>MAR expression may have inhibited functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="371">
                    <text>Mad-3 also has the ability to inhibit functional activation of a plasmid HIV reporter by p49/ p65 in transient transfected T-cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="372">
                    <text>Mad-3 also inhibited functional activation of a plasmid HIV reporter by p49/ p65 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="373">
                    <text>Mad-3 can fully inhibit functional activation of an HIV reporter plasmid by p49/p65 that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="374">
                    <text>Mad-3 co-expression (NO) inhibiting functional activation of an HIV reporter plasmid by p49/p65 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="375">
                    <text>Mad-3 co-expression also inhibited functional activation of an HIV reporter plasmid by p49/p65 in transfected T-leukemia cells transfected.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="376">
                    <text>Mad-3 co-expression also inhibits functional activation of an HIV reporter plasmid by p49/p65 in transient transfected T-cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="377">
                    <text>Mad-3 co-expression inhibited functional activation of an HIV reporter plasmid by p49/p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="378">
                    <text>Mad-3 co-expression is able to inhibit functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="379">
                    <text>Mad-3 co-expression may also have inhibited functional activation of an HIV reporter plasmid by p49/p65 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="380">
                    <text>Mad-3 co-expression may have completely inhibited functional activation of an HIV reporter plasmid by p49/p65 which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="381">
                    <text>Mad-3 inhibited functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="382">
                    <text>Mad-3 inhibited functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="383">
                    <text>Mad-3 inhibits functional activation of a plasmid HIV reporter by p49/ p65 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="384">
                    <text>Mad-3 may also have inhibited functional activation of a plasmid HIV reporter by p49/ p65 in T cells affected by jurkat.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="385">
                    <text>Mad-3 may also have inhibited functional activation of a plasmid HIV reporter by p49/ p65 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="386">
                    <text>Mad-3 may also have inhibited functional activation of an HIV reporter plasmid by p49/p65 in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="387">
                    <text>Mad-3 may have completely inhibited functional activation of a plasmid HIV reporter by p49/ p65 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="388">
                    <text>NK cell-mediated cytotoxicity in Jurkat T-leukemia transfect cells has also been inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="389">
                    <text>NK cell-mediated cytotoxicity in transfectuously affected T-leukemia cells, wil is also inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="390">
                    <text>NK cell-mediated cytotoxicity in transfectuously affected T-leukemia cells, wil is also inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="391">
                    <text>NK cell-mediated cytotoxicity in transiently transfected Jurkat T-cells was also inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="392">
                    <text>NK cell-mediated cytotoxicity in transiently transfected Jurkat T-cells was also inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="393">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and can be fully inhibited with cell surface receptors for immunoglobulin superfamilies and type C lectins, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="394">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and is fully inhibited with cell surface receptors of immunoglobulin and C-type superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="395">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and is observed to be totally inhibited with cell surface receptors for immunoglobulin superfamilies and type C lectins, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="396">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and is observed to be totally inhibited with cell surface receptors of immunoglobulin and C-type superfamilies, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="397">
                    <text>NK cell-mediated cytotoxicity is a dependent and saturable concentration and was fully inhibited with cell surface receptors of immunoglobulin and Clectin superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="398">
                    <text>NK cell-mediated cytotoxicity is able to be inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="399">
                    <text>NK cell-mediated cytotoxicity is capable of being inhibited by cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="400">
                    <text>NK cell-mediated cytotoxicity is concentration-dependent and saturable and is able to be fully inhibited with cell surface receptors of immunoglobulin and C-type superfamilies , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="401">
                    <text>NK cell-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin superfamilies and type C lectins which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="402">
                    <text>NK cell-mediated cytotoxicity is inhibited by cell surface receptors of immunoglobulin and C-type superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="403">
                    <text>NK cell-mediated cytotoxicity was inhibited by cell surface receptors of immunoglobulin and C-type superfamilies that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="404">
                    <text>NK cell-mediated cytotoxicity will be inhibited by cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="405">
                    <text>NK-mediated cytotoxicity has been inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="406">
                    <text>NK-mediated cytotoxicity in T cells of Jurkat transfects is also inhibited by cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="407">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be totally inhibited with cell surface receptors for immunoglobulin and C-type lectin superfamilies, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="408">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and can be totally inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="409">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is fully inhibited with cell surface receptors for immunoglobulin and C-type lectin superfamilies, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="410">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is observed to be totally inhibited with cell surface receptors for the superfamilies of immunoglobulin and type C lectin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="411">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and was fully inhibited with cellular surface receptors for immunoglobulin and C-type lectin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="412">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="413">
                    <text>NK-mediated cytotoxicity is concentration-dependent and saturable and is able to be fully inhibited with cell surface receptors for immunoglobulin and C-type lectin superfamilies , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="414">
                    <text>NK-mediated cytotoxicity may have been inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="415">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="416">
                    <text>NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="417">
                    <text>PDE44 cyclic AMP-specific isoforms is strongly inhibited by rolipram by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="418">
                    <text>PDE44 cyclic AMP-specific phosphodiesterase has been strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="419">
                    <text>PDE4C is one of the four mammalian genes that codify PDE44 cyclic AMP-phosphodiesterases and is inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="420">
                    <text>PDE4C is one of the four mammalian genes that codify PDE44 cyclic AMP-specific isoforms that have been inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="421">
                    <text>PDE4C is one of the four mammalian genes that codify PDE44 cyclic AMP-specific phosphodiesterase inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="422">
                    <text>PDE4C is one of the four mammalian genes that codify both C alpha and C beta isoforms of the catalytic subunit PKA inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="423">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA and is inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="424">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="425">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA that have been inhibited by protein extracts from transcedit body cells.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="426">
                    <text>PDE4C is one of the four mammalian genes that codify both the alpha and C beta isoforms of the catalytic subunit PKA that have been inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="427">
                    <text>PDE4C is one of the four mammalian genes that codify both the isoforms C alpha and C beta of the catalytic subunit PKA inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="428">
                    <text>PDE4C is one of the four mammalian genes that codify multiple PDE4-specific phosphodiesterase isoforms that have been inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="429">
                    <text>Protease A0 inhibitors (MG132 and lactactacylin) are able to inhibit binding.</text>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="430">
                    <text>Roipram can strongly inhibit multiple PDE4-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="431">
                    <text>Roipram has strongly inhibited multiple PDE4 by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="432">
                    <text>Roipram has strongly inhibited multiple PDE4-specific phosphodiesterase isoforms by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="433">
                    <text>Roipram has the ability to strongly inhibit multiple PDE4 by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="434">
                    <text>Roipram has the ability to strongly inhibit multiple PDE4-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="435">
                    <text>Roipram inhibits multiple PDE4 isoforms coded by PDE4C codified by PDE4C.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="436">
                    <text>Roipram is able to inhibit multiple PDE4.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="437">
                    <text>Roipram is able to strongly inhibit multiple PDE4-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="438">
                    <text>Roipram strongly inhibited multiple PDE4 isoforms coded by PDE4C by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="439">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I may have completely inhibited late events of clathrin-coated vesicles formation that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="440">
                    <text>The A0 inhibitors of the MG132 protoisoma and laactacylin have the ability to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="441">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="442">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="443">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then cytotoxicity mediated by NK cells was inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="444">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="445">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then GadX-dependent activation was inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent activation</arg>
                </example>
                <example src="PERMUTATE" no="446">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then GadX-dependent was about to be inhibited by 50 mg/ml GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="447">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity has been inhibited by 50 mg/ml cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="448">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity has been inhibited by 50 mg/ml cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="449">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="450">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="451">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK cell-mediated cytotoxicity will be inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="452">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity has been inhibited by 50 mg/ml cell surface receptors for the superfamilies of immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="453">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity will be inhibited by 50 mg/ml cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="454">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then activity promotionAp2 was about to be inhibited by 50 mg/ml CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="455">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then activity promotionAp2 was inhibited by 50 mg/ml CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="456">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then binding was inhibited by 50 mg/ml DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="457">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 has been inhibited by 50 mg/ml primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="458">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 has been inhibited by 50 mg/ml MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="459">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by 50 mg/ml MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="460">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by 50 mg/ml co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="461">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV plasmid reporter for p49/p65 was inhibited by 50 mg/ml AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="462">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was inhibited by 50 mg/ml MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="463">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin coated vesicles formation events was about to be inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="464">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events will be inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="465">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicles formation events will be inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="466">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand has been inhibited by 50 mg/ml DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="467">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then ligand has been inhibited by 50 mg/ml EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="468">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then negative regulation of Stat4, Stat5 and Stat6 phosphorylated will be inhibited by 50 mg/ml GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="469">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then reduced regulation of Stat4, Stat5 and Stat6 was about to be inhibited by 50 mg/ml proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="470">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then the regulation of phosphorylated state, state5 and state6 was inhibited by 50 mg/ml a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="471">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then the regulation of the phosphorylated state, Stat5 and Stat6 was inhibited by 50 mg/ml inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="472">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then NK cell-mediated cytotoxicity will be inhibited by 50 mg/ml of cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="473">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then NK-mediated cytotoxicity will be inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="474">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then depending on GadX will be inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="475">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by 50 mg/ml of Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="476">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then functional activation of a plasmid HIV reporter by p49/ p65 will be inhibited by 50 mg/ml of co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="477">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then functional activation of an HIV reporter plasmid by p49/p65 will be inhibited by 50 mg/ml of Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="478">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then late clathrin-coated vesicles formation events will be inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="479">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then ligand will be inhibited by 50 mg/ml of DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="480">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then reduced regulation of Stat4, Stat5 and Stat6 will be inhibited by 50 mg/ml of proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="481">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml CRP-cAMP complex to inhibiting gnAp2 promoting activity.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="482">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml GM132 proteasome inhibitors and laactacytin to inhibiting negative regulation of Stat4, Stat5 and Stat6 phosphorylated.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="483">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml GadW to inhibiting depending on GadX.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="484">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml Mad-3 to inhibiting functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="485">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml cell surface receptors for immunoglobulin and C-type lectin superfamilies to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="486">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml co-expression of AAM-3 to inhibiting functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="487">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml nitric oxide to inhibiting platelet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="488">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I to inhibiting late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="489">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of 10 mM EDTA to inhibiting ligand.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="490">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of CRP-cAMP complex to inhibiting activity promotionAp2.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="491">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of DTA of 10 mM to inhibiting ligand.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="492">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of EDTA 10mM to inhibiting binding.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="493">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of MAR expression to inhibiting functional activation of a plasmid HIV reporter by p49/ p65.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="494">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of Mad-3 co-expression to inhibiting functional activation of an HIV reporter plasmid by p49/p65.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="495">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of inhibitors of the MG132 proteasome and lactacyttin to inhibiting the regulation of the phosphorylated state, Stat5 and Stat6.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="496">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then GadX-dependent was inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">GadX-dependent</arg>
                </example>
                <example src="PERMUTATE" no="497">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and C-type lectin superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="498">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then cytotoxicity mediated by NK cells was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="499">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then depending on GadX was inhibited by 50 mg/ml of GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="500">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then descendant regulation of phosphorylation state, state5 and state6 was inhibited by 50 mg/ml of primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="501">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then gnAp2 promoting activity was inhibited by 50 mg/ml of CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="502">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="503">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then ligand was inhibited by 50 mg/ml of EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="504">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then platquet function was inhibited by 50 mg/ml of nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="505">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then reduced regulation of Stat4, Stat5 and Stat6 was inhibited by 50 mg/ml of proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="506">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK cell-mediated cytotoxicity is inhibited by 50 mg/ml of cell surface receptors for immunoglobulin superfamilies and type C lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="507">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK cell-mediated cytotoxicity is inhibited by 50 mg/ml of cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="508">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors of immunoglobulin and C-type superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="509">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK cell-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors of immunoglobulin and Clectin superfamilies.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="510">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was about to be inhibited by 50 mg/ml of cellular surface receptors for immunoglobulin and C-type lectin.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="511">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then binding is inhibited by 50 mg/ml of EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="512">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was about to be inhibited by 50 mg/ml of MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="513">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by 50 mg/ml of co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="514">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of an HIV plasmid reporter for p49/p65 is inhibited by 50 mg/ml of AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="515">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of an HIV plasmid reporter for p49/p65 was about to be inhibited by 50 mg/ml of AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="516">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then functional activation of an HIV reporter plasmid by p49/p65 was about to be inhibited by 50 mg/ml of Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="517">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicle formation events was about to be inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="518">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="519">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late clathrin-coated vesicles formation events was about to be inhibited by 50 mg/ml of the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="520">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late events of clathrin-coated vesicles formation was inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="521">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then ligand was about to be inhibited by 50 mg/ml of DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="522">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then platquet function was about to be inhibited by 50 mg/ml of nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="523">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then the regulation of phosphorylated state, state5 and state6 was about to be inhibited by 50 mg/ml of a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="524">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit ligand involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="525">
                    <text>This synthetic peptide binding to P can inhibit its C3b binding.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its C3b binding</arg>
                </example>
                <example src="PERMUTATE" no="526">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and PDE44 cyclic AMP-specific isoforms can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="527">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and both the alpha and C beta isoforms of the catalytic subunit PKA can be inhibited by protein extracts from transcent body cells.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="528">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple PDE4 can be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="529">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="530">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple PDE4-specific phosphodiesterase isoforms can be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="531">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and rolipram is able to inhibit PDE44 cyclic AMP-phosphodiesterases equally.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="532">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and rolipram is able to inhibit multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms equally.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="533">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that CRP-cAMP could have inhibited sigma (54)-dependent glnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-dependent glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="534">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that CRP-cAMP could have inhibited sigma (54)-gnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="535">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that Roipram could have inhibited multiple PDE4 with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="536">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that protein extracts of transcedural body cells could have inhibited both alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="537">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that rolipram could have inhibited PDE44 cyclic AMP-specific isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="538">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and CRP-cAMP can inhibit sigma (54) - glnAp2 equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="539">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and protein extracts from the transcedit body cells can inhibit both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="540">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and protein extracts from transfected body cells can inhibit both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="541">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and rolipram can inhibit PDE44 cyclic AMP-phosphodiesterases equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="542">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and rolipram can inhibit PDE44 cyclic AMP-specific isoforms equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific isoforms</arg>
                </example>
                <example src="PERMUTATE" no="543">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that CRP-cAMP has inhibited depending on sigma (54)-gnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="544">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that CRP-cAMP has inhibited sigma (54) - glnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="545">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that Roipram has inhibited multiple PDE4 with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="546">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that Roipram has inhibited multiple PDE4-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="547">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that rolipram has inhibited multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="548">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that Roipram inhibits multiple PDE4 equally effectively.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="549">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that protein extracts from transcedit body cells inhibits both the alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="550">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and PDE44 cyclic AMP-specific phosphodiesterase can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="551">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the alpha and C beta isoforms of the catalytic subunit PKA are observed to be inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="552">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the alpha and C beta isoforms of the catalytic subunit PKA can be inhibited by protein extracts from transcent body cells.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="553">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple PDE4 isoforms coded by PDE4C can be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="554">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple PDE4-specific phosphodiesterase isoforms can be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="555">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and sigma (54) - glnAp2 are observed to be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="556">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and sigma (54)-gnAp2 dependent can be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="557">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts of infected body cells.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="558">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="559">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                </example>
                <example src="PERMUTATE" no="560">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by Roipram.</text>
                    <arg n="0">Roipram</arg>
                </example>
                <example src="PERMUTATE" no="561">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and CRP-cAMP can inhibit sigma (54)-gnAp2 dependent with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="562">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and CRP-cAMP can inhibit sigma (54)-gnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="563">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and protein extracts from transcedit body cells can inhibit both the alpha and C beta isoforms of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="564">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that CRP-cAMP is capable of inhibiting depending on sigma (54)-gnAp2 equally effectively.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="565">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that Roipram is capable of inhibiting multiple PDE4 equally effectively.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4</arg>
                </example>
                <example src="PERMUTATE" no="566">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that Roipram is capable of inhibiting multiple PDE4-specific phosphodiesterase isoforms equally effectively.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="567">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that protein extracts from transfected body cells is capable of inhibiting both C alpha and C beta isoforms of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="568">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that protein extracts of the transfected body cells is capable of inhibiting both the isoforms C alpha and C beta of the catalytic subunit PKA equally effectively.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="569">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts of the transfected body cells.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                </example>
                <example src="PERMUTATE" no="570">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and sigma (54) - glnAp2 will be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54) - glnAp2</arg>
                </example>
                <example src="PERMUTATE" no="571">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and sigma (54)-gnAp2 dependent will be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2 dependent</arg>
                </example>
                <example src="PERMUTATE" no="572">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and sigma (54)-gnAp2 will be inhibited by CRP-cAMP.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="573">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by protein extracts of transfected cells.</text>
                    <arg n="0">protein extracts of transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="574">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and CRP-cAMP inhibited depending on sigma (54)-gnAp2 with equal effectiveness.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="575">
                    <text>Transient overexpression in the cells found that a thermostable inhibitor of the protein kinase was produced by human PKI cDNA, and rolipram inhibited multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="576">
                    <text>a proteasome MG132 inhibitor and lactacitstin also inhibits the regulation of phosphorylated state, state5 and state6 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="577">
                    <text>a proteasome MG132 inhibitor and lactacitstin inhibited the regulation of phosphorylated state, state5 and state6 activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="578">
                    <text>activity promotionAp2 is a dependent and saturable concentration and is able to be fully inhibited with CRP-cAMP complex, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="579">
                    <text>activity promotionAp2 will be inhibited by CRP-cAMP complex which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">activity promotionAp2</arg>
                </example>
                <example src="PERMUTATE" no="580">
                    <text>an inhibitor of the MG132 protein and lactacittine (NO) inhibiting regulation of phosphorylated status, stage 5 and stage 6 activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="581">
                    <text>an inhibitor of the MG132 protein and lactacittine activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit regulation of phosphorylated status, stage 5 and stage 6.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="582">
                    <text>an inhibitor of the MG132 protein and lactacittine fully inhibiting concentration-dependent regulation of phosphorylated status, stage 5 and stage 6 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="583">
                    <text>an inhibitor of the MG132 protein and lactacittine inhibited regulation of phosphorylated status, stage 5 and stage 6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="584">
                    <text>an inhibitor of the MG132 protein and lactacittine may have completely inhibited regulation of phosphorylated status, stage 5 and stage 6 that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="585">
                    <text>another protein binding to phosphatase may have inhibited the function or location of A1.</text>
                    <arg n="0">another protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="586">
                    <text>binding are inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="587">
                    <text>binding has been inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="588">
                    <text>binding in T cells of Jurkat transfects is also inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="589">
                    <text>binding in T-lycemic cells transfected, wil is also inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="590">
                    <text>binding in transiently transfected Jurkat T-cells is also inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="591">
                    <text>binding is a dependent and saturable concentration and can be fully inhibited with DTA of 10 mM, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="592">
                    <text>binding is a dependent and saturable concentration and is observed to be totally inhibited with EDTA 10mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="593">
                    <text>binding may have been inhibited by DTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="594">
                    <text>binding was inhibited by EDTA 10mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="PERMUTATE" no="595">
                    <text>both the alpha and C beta isoforms of the catalytic subunit PKA is observed to be strongly inhibited by protein extracts from transfected body cells, by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="596">
                    <text>both the isoforms C alpha and C beta of the catalytic subunit PKA is strongly inhibited by protein extracts of the transfected body cells by 21-fold.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="597">
                    <text>both the isoforms C alpha and C beta of the catalytic subunit PKA was strongly inhibited by protein extracts of the transfected body cells 21 times.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="598">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="599">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies can totally inhibit NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="600">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="601">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies may also have inhibited NK-mediated cytotoxicity in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="602">
                    <text>cell surface receptors for immunoglobulin and C-type lectin superfamilies may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and C-type lectin superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="603">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="604">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="605">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins also inhibits NK-mediated cytotoxicity in transient transfected T-cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="606">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins co-expression also has the ability to inhibit cytotoxicity mediated by NK cells in T-leukemia transnetly affected cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="607">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins fully inhibiting concentration-dependent NK-mediated cytotoxicity and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="608">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins is able to inhibit cytotoxicity mediated by NK cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="609">
                    <text>cell surface receptors for immunoglobulin superfamilies and C-type lectins may have inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="610">
                    <text>cell surface receptors for immunoglobulin superfamilies and type C lectins may have completely inhibited NK cell-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and type C lectins</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="611">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="612">
                    <text>cell surface receptors for the superfamilies of immunoglobulin and type C lectin may also have inhibited NK-mediated cytotoxicity in T cells affected by jurkat.</text>
                    <arg n="0">cell surface receptors for the superfamilies of immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="613">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="614">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="615">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies also inhibits NK cell-mediated cytotoxicity in transiently transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="616">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies has also inhibited NK cell-mediated cytotoxicity in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="617">
                    <text>cell surface receptors of immunoglobulin and C-type superfamilies is able to inhibit NK cell-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and C-type superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="618">
                    <text>cell surface receptors of immunoglobulin and Clectin superfamilies inhibits NK cell-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors of immunoglobulin and Clectin superfamilies</arg>
                    <arg n="2">NK cell-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="619">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="620">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin also inhibits NK-mediated cytotoxicity in transiently transfected T-leukemia cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="621">
                    <text>cellular surface receptors for immunoglobulin and C-type lectin may have completely inhibited NK-mediated cytotoxicity which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cellular surface receptors for immunoglobulin and C-type lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="PERMUTATE" no="622">
                    <text>chloramphenicol can fully inhibit protein synthesis that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="623">
                    <text>chloramphenicol inhibited protein synthesis activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="624">
                    <text>chloramphenicol inhibits protein synthesis activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="625">
                    <text>co-expression of AAM-3 (NO) inhibiting functional activation of a plasmid HIV reporter by p49/ p65 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="626">
                    <text>cytotoxicity mediated by NK cells in transiently transfected Jurkat T-cells is also inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="627">
                    <text>cytotoxicity mediated by NK cells in transiently transfected Jurkat T-cells was also inhibited by cell surface receptors for immunoglobulin superfamilies and C-type lectins.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="628">
                    <text>cytotoxicity mediated by NK cells is a dependent and saturable concentration and has been totally inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="629">
                    <text>cytotoxicity mediated by NK cells is a dependent and saturable concentration and is able to be fully inhibited with cell surface receptors for immunoglobulin superfamilies and C-type lectins, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin superfamilies and C-type lectins</arg>
                    <arg n="2">cytotoxicity mediated by NK cells</arg>
                </example>
                <example src="PERMUTATE" no="630">
                    <text>depending on GadX in transfectuously affected T-leukemia cells, wil is also inhibited by GadW.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="631">
                    <text>depending on GadX is a dependent and saturable concentration and is observed to be totally inhibited with GadW, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GadW</arg>
                    <arg n="2">depending on GadX</arg>
                </example>
                <example src="PERMUTATE" no="632">
                    <text>depending on sigma (54)-gnAp2 has been strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">depending on sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="633">
                    <text>descendant regulation of phosphorylation state, state5 and state6 in T cells of Jurkat transfects is also inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="634">
                    <text>descendant regulation of phosphorylation state, state5 and state6 in transfectuously affected T-leukemia cells, wil is also inhibited by primary proteasome inhibitors MG132 and lactacyttin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="635">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is a dependent and saturable concentration and has been totally inhibited with primary proteasome inhibitors MG132 and lactacyttin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="636">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is able to be inhibited by primary proteasome inhibitors MG132 and lactacitstin.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="637">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is capable of being inhibited by primary proteasome inhibitors MG132 and lactacitstin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="638">
                    <text>descendant regulation of phosphorylation state, state5 and state6 is capable of being inhibited by primary proteasome inhibitors MG132 and lactacyttin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="639">
                    <text>descendant regulation of phosphorylation state, state5 and state6 was inhibited by primary proteasome inhibitors MG132 and lactacyttin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="640">
                    <text>descending regulation of the phosphorylation status, state5 and state6 in T cells of Jurkat transfects is also inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="641">
                    <text>descending regulation of the phosphorylation status, state5 and state6 in transfectuously affected T-leukemia cells, wil is also inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="642">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is a dependent and saturable concentration and has been totally inhibited with mainly the inhibitors of the MG132 proteasome and lactacittina, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="643">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is a dependent and saturable concentration and is fully inhibited with mainly the inhibitors of the MG132 proteasome and lactacittina, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="644">
                    <text>descending regulation of the phosphorylation status, state5 and state6 is capable of being inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="645">
                    <text>descending regulation of the phosphorylation status, state5 and state6 was inhibited by mainly the inhibitors of the MG132 proteasome and lactacittina.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="646">
                    <text>function and location of phosphateases will be inhibited if phosphatase is associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">function and location of phosphateases</arg>
                </example>
                <example src="PERMUTATE" no="647">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 are inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="648">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in T-lycemic cells transfected, wil is also inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="649">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in T-lycemic cells transfected, wil is also inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="650">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transfectuously affected T-leukemia cells, wil is also inhibited by co-expression of AAM-3.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="651">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected Jurkat T-cells is also inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="652">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 in transiently transfected Jurkat T-cells was also inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="653">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and can be fully inhibited with MAR expression, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="654">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is a dependent and saturable concentration and is observed to be totally inhibited with MAD-3 co-expression, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="655">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is able to be inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="656">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is concentration-dependent and saturable and is able to be fully inhibited with MAR expression , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="657">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="658">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="659">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 is inhibited by co-expression of AAM-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">co-expression of AAM-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="660">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAD-3 co-expression.</text>
                    <arg n="0">MAD-3 co-expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="661">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by MAR expression.</text>
                    <arg n="0">MAR expression</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="662">
                    <text>functional activation of a plasmid HIV reporter by p49/ p65 was inhibited by Mad-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of a plasmid HIV reporter by p49/ p65</arg>
                </example>
                <example src="PERMUTATE" no="663">
                    <text>functional activation of an HIV plasmid reporter for p49/p65 in transiently transfected Jurkat T-cells was also inhibited by AAM-3 expression.</text>
                    <arg n="0">AAM-3 expression</arg>
                    <arg n="2">functional activation of an HIV plasmid reporter for p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="664">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 can be inhibited by Mad-3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="665">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in Jurkat T-leukemia transfect cells has also been inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="666">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in T-lycemic cells transfected, wil is also inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="667">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 in transiently transfected Jurkat T-cells was also inhibited by MAD-3 expression.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="668">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is capable of being inhibited by Mad-3 co-expression.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="669">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is concentration-dependent and saturable and is able to be fully inhibited with MAD-3 expression , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">MAD-3 expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="670">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 is concentration-dependent and saturable and is able to be fully inhibited with Mad-3 co-expression , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Mad-3 co-expression</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="671">
                    <text>functional activation of an HIV reporter plasmid by p49/p65 was inhibited by Mad-3.</text>
                    <arg n="0">Mad-3</arg>
                    <arg n="2">functional activation of an HIV reporter plasmid by p49/p65</arg>
                </example>
                <example src="PERMUTATE" no="672">
                    <text>gnAp2 promoting activity has been inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="673">
                    <text>gnAp2 promoting activity in Jurkat T-leukemia transfect cells has also been inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="674">
                    <text>gnAp2 promoting activity in transiently transfected Jurkat T-cells is also inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="675">
                    <text>gnAp2 promoting activity in transiently transfected Jurkat T-cells was also inhibited by CRP-cAMP complex.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="676">
                    <text>gnAp2 promoting activity is a dependent and saturable concentration and can be fully inhibited with CRP-cAMP complex, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="677">
                    <text>gnAp2 promoting activity is a dependent and saturable concentration and is observed to be totally inhibited with CRP-cAMP complex, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">CRP-cAMP complex</arg>
                    <arg n="2">gnAp2 promoting activity</arg>
                </example>
                <example src="PERMUTATE" no="678">
                    <text>inhibitors of the MG132 proteasome and lactacyttin fully inhibiting concentration-dependent the regulation of the phosphorylated state, Stat5 and Stat6 and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="679">
                    <text>its function or location would be inhibited if phosphatease is associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="680">
                    <text>late clathrin coated vesicles formation events is a dependent and saturable concentration and can be fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="681">
                    <text>late clathrin coated vesicles formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="682">
                    <text>late clathrin-coated vesicle formation events in transiently transfected Jurkat T-cells is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="683">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and has been totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="684">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and is fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="685">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and was fully inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="686">
                    <text>late clathrin-coated vesicle formation events is capable of being inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="687">
                    <text>late clathrin-coated vesicles formation events in T-lycemic cells transfected, wil is also inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="688">
                    <text>late clathrin-coated vesicles formation events is capable of being inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="689">
                    <text>late clathrin-coated vesicles formation events may have been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="690">
                    <text>late events of clathrin-coated vesicles formation are inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="691">
                    <text>late events of clathrin-coated vesicles formation in transfectuously affected T-leukemia cells, wil is also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="692">
                    <text>late events of clathrin-coated vesicles formation is capable of being inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="693">
                    <text>late events of clathrin-coated vesicles formation is inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="694">
                    <text>late events of clathrin-coated vesicles formation is observed to be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="PERMUTATE" no="695">
                    <text>ligand are inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="696">
                    <text>ligand are inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="697">
                    <text>ligand in Jurkat T-leukemia transfect cells has also been inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="698">
                    <text>ligand in T-lycemic cells transfected, wil is also inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="699">
                    <text>ligand in T-lycemic cells transfected, wil is also inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="700">
                    <text>ligand in transfectuously affected T-leukemia cells, wil is also inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="701">
                    <text>ligand in transiently transfected Jurkat T-cells was also inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="702">
                    <text>ligand is a dependent and saturable concentration and can be totally inhibited with EDTA 10mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="703">
                    <text>ligand is able to be inhibited by EDTA 10mM.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="704">
                    <text>ligand is able to be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="705">
                    <text>ligand is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="706">
                    <text>ligand is inhibited by EDTA 10mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA 10mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="707">
                    <text>ligand was inhibited by DTA of 10 mM that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="708">
                    <text>ligand was inhibited by DTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="709">
                    <text>ligand was inhibited by DTA of 10 mM.</text>
                    <arg n="0">DTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="710">
                    <text>ligand will be inhibited by 10 mM EDTA.</text>
                    <arg n="0">10 mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="711">
                    <text>ligand will be inhibited by EDTA of 10 mM which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="PERMUTATE" no="712">
                    <text>mainly the inhibitors of the MG132 proteasome and lactacittina also inhibits descending regulation of the phosphorylation status, state5 and state6 in transient transfected T-cells.</text>
                    <arg n="0">mainly the inhibitors of the MG132 proteasome and lactacittina</arg>
                    <arg n="2">descending regulation of the phosphorylation status, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="713">
                    <text>multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms was strongly inhibited by rolipram 21 times.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="714">
                    <text>multiple PDE4 isoforms coded by PDE4C has been strongly inhibited by Roipram, by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="715">
                    <text>multiple PDE4 isoforms coded by PDE4C is strongly inhibited by Roipram by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4 isoforms coded by PDE4C</arg>
                </example>
                <example src="PERMUTATE" no="716">
                    <text>multiple PDE4-specific phosphodiesterase isoforms is observed to be strongly inhibited by Roipram, by 21-folds.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="717">
                    <text>multiple PDE4-specific phosphodiesterase isoforms is strongly inhibited by Roipram, by 21-fold.</text>
                    <arg n="0">Roipram</arg>
                    <arg n="1">multiple PDE4-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="718">
                    <text>multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms is strongly inhibited by rolipram by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="719">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated in transiently transfected Jurkat T-cells was also inhibited by GM132 proteasome inhibitors and laactacytin.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="720">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is a dependent and saturable concentration and can be totally inhibited with GM132 proteasome inhibitors and laactacytin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="721">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated is a dependent and saturable concentration and is fully inhibited with GM132 proteasome inhibitors and laactacytin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="722">
                    <text>negative regulation of Stat4, Stat5 and Stat6 phosphorylated will be inhibited by GM132 proteasome inhibitors and laactacytin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">GM132 proteasome inhibitors and laactacytin</arg>
                    <arg n="2">negative regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="PERMUTATE" no="723">
                    <text>nitric oxide (NO) inhibiting platquet function activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="724">
                    <text>nitric oxide can fully inhibit platelet function that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="725">
                    <text>nitric oxide co-expression also has the ability to inhibit platquet function in T-leukemia transnetly affected cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="726">
                    <text>nitric oxide has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">nitric oxide</arg>
                </example>
                <example src="PERMUTATE" no="727">
                    <text>nitric oxide is able to inhibit platquet function.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="728">
                    <text>nitric oxide may also have inhibited platquet function in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="729">
                    <text>other protein binding to phosphatase may have inhibited its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="730">
                    <text>other protein binding to phosphatease can inhibit the function of phosphateases and localization.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function of phosphateases and localization</arg>
                </example>
                <example src="PERMUTATE" no="731">
                    <text>other protein binds to phosphatase and is able to inhibit its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="732">
                    <text>other protein binds to phosphatase to inhibit its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatase</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="733">
                    <text>other protein binds to phosphatease to inhibit its function or location.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">its function or location</arg>
                </example>
                <example src="PERMUTATE" no="734">
                    <text>other protein binds to phosphatease to inhibit the function or location of A1.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="735">
                    <text>platelet function are inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="736">
                    <text>platelet function is a dependent and saturable concentration and is able to be fully inhibited with nitric oxide, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="737">
                    <text>platelet function is capable of being inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="738">
                    <text>platelet function is inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="739">
                    <text>platelet function is observed to be inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platelet function</arg>
                </example>
                <example src="PERMUTATE" no="740">
                    <text>platquet function are inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="741">
                    <text>platquet function in transiently transfected Jurkat T-cells is also inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="742">
                    <text>platquet function is capable of being inhibited by nitric oxide.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="743">
                    <text>platquet function is inhibited by nitric oxide which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">nitric oxide</arg>
                    <arg n="2">platquet function</arg>
                </example>
                <example src="PERMUTATE" no="744">
                    <text>primary proteasome inhibitors MG132 and lactacitstin (NO) inhibiting descendant regulation of phosphorylation state, state5 and state6 activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="745">
                    <text>primary proteasome inhibitors MG132 and lactacitstin inhibited descendant regulation of phosphorylation state, state5 and state6 activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="746">
                    <text>primary proteasome inhibitors MG132 and lactacitstin may have inhibited descendant regulation of phosphorylation state, state5 and state6.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacitstin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="747">
                    <text>primary proteasome inhibitors MG132 and lactacyttin co-expression also has the ability to inhibit descendant regulation of phosphorylation state, state5 and state6 in T-leukemia transnetly affected cells.</text>
                    <arg n="0">primary proteasome inhibitors MG132 and lactacyttin</arg>
                    <arg n="2">descendant regulation of phosphorylation state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="748">
                    <text>proteasome inhibitors MG132 and lactacistin also inhibits reduced regulation of Stat4, Stat5 and Stat6 in transiently transfected T-leukemia cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="749">
                    <text>proteasome inhibitors MG132 and lactacistin can inhibit reduced regulation of Stat4, Stat5 and Stat6.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="750">
                    <text>protein extracts from the transcedit body cells strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from the transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="751">
                    <text>protein extracts from transcedit body cells has the ability to inhibit phosphorylase-specific both the alpha and C beta isoforms of the catalytic subunit PKA-isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="752">
                    <text>protein extracts from transcedit body cells is able to inhibit both the alpha and C beta isoforms of the catalytic subunit PKA.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="753">
                    <text>protein extracts from transcedit body cells strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transcedit body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="754">
                    <text>protein extracts from transcent body cells can strongly inhibit both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="755">
                    <text>protein extracts from transcent body cells strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transcent body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="756">
                    <text>protein extracts from transfect body cells has the ability to strongly inhibit both the isoforms C alpha and beta C of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="757">
                    <text>protein extracts from transfect body cells inhibited both the isoforms C alpha and beta C of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the isoforms C alpha and beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="758">
                    <text>protein extracts from transfected body cells has strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="759">
                    <text>protein extracts from transfected body cells has the ability to strongly inhibit both C alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both C alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="760">
                    <text>protein extracts from transfected body cells may have strongly inhibited both the alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both the alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="761">
                    <text>protein extracts from transfected cells inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">protein extracts from transfected cells</arg>
                </example>
                <example src="PERMUTATE" no="762">
                    <text>protein extracts of infected body cells has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">protein extracts of infected body cells</arg>
                </example>
                <example src="PERMUTATE" no="763">
                    <text>protein extracts of the transfected body cells has the ability to strongly inhibit both the isoforms C alpha and C beta of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="764">
                    <text>protein extracts of the transfected body cells has the ability to strongly inhibit both the isoforms C alpha and C beta of the catalytic subunit PKA by 21-folds.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="765">
                    <text>protein extracts of the transfected body cells inhibited both the isoforms C alpha and C beta of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="766">
                    <text>protein extracts of the transfected body cells may inhibit both the isoforms C alpha and C beta of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts of the transfected body cells</arg>
                    <arg n="1">both the isoforms C alpha and C beta of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="767">
                    <text>protein extracts of transcedural body cells can strongly inhibit both alpha and C beta isoforms of the catalytic subunit PKA by 21-fold.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="768">
                    <text>protein extracts of transcedural body cells is able to inhibit both alpha and C beta isoforms of the catalytic subunit PKA coded by PDE4C.</text>
                    <arg n="0">protein extracts of transcedural body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit PKA</arg>
                </example>
                <example src="PERMUTATE" no="769">
                    <text>protein synthesis in transiently transfected Jurkat T-cells was also inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="770">
                    <text>protein synthesis is a dependent and saturable concentration and is observed to be totally inhibited with chloramphenicol, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="771">
                    <text>protein synthesis is observed to be inhibited by chloramphenicol.</text>
                    <arg n="0">chloramphenicol</arg>
                    <arg n="2">protein synthesis</arg>
                </example>
                <example src="PERMUTATE" no="772">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is a dependent and saturable concentration and has been totally inhibited with proteasome inhibitors MG132 and lactacistin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="773">
                    <text>reduced regulation of Stat4, Stat5 and Stat6 is inhibited by proteasome inhibitors MG132 and lactacistin.</text>
                    <arg n="0">proteasome inhibitors MG132 and lactacistin</arg>
                    <arg n="2">reduced regulation of Stat4, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="774">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 in transiently transfected Jurkat T-cells is also inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="775">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is a dependent and saturable concentration and was fully inhibited with an inhibitor of the MG132 protein and lactacittine, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="776">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="777">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 is observed to be inhibited by an inhibitor of the MG132 protein and lactacittine.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="778">
                    <text>regulation of phosphorylated status, stage 5 and stage 6 was inhibited by an inhibitor of the MG132 protein and lactacittine that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">an inhibitor of the MG132 protein and lactacittine</arg>
                    <arg n="2">regulation of phosphorylated status, stage 5 and stage 6</arg>
                </example>
                <example src="PERMUTATE" no="779">
                    <text>rolipram can strongly inhibit PDE44 cyclic AMP-specific phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="780">
                    <text>rolipram can strongly inhibit multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="781">
                    <text>rolipram has strongly inhibited PDE44 cyclic AMP-specific phosphodiesterase by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="782">
                    <text>rolipram has strongly inhibited multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="783">
                    <text>rolipram has the ability to inhibit phosphorylase-specific PDE44 cyclic AMP-specific phosphodiesterase-isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-specific phosphodiesterase</arg>
                </example>
                <example src="PERMUTATE" no="784">
                    <text>rolipram has the ability to inhibit phosphorylase-specific multiple AMP-specific cyclic PDE4 isoforms-isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="785">
                    <text>rolipram has the ability to strongly inhibit PDE44 cyclic AMP-phosphodiesterases by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="786">
                    <text>rolipram has the ability to strongly inhibit PDE44 cyclic AMP-phosphodiesterases by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="787">
                    <text>rolipram inhibited multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="788">
                    <text>rolipram inhibited multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="789">
                    <text>rolipram inhibits multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms codified by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple PDE4 cyclics AMP-specific phosphodiesterase isoforms</arg>
                </example>
                <example src="PERMUTATE" no="790">
                    <text>rolipram is able to inhibit multiple AMP-specific cyclic PDE4 isoforms.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific cyclic PDE4 isoforms</arg>
                </example>
                <example src="PERMUTATE" no="791">
                    <text>rolipram may inhibit PDE44 cyclic AMP-phosphodiesterases coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">PDE44 cyclic AMP-phosphodiesterases</arg>
                </example>
                <example src="PERMUTATE" no="792">
                    <text>sigma (54)-gnAp2 has been strongly inhibited by CRP-cAMP, by 21-fold.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="793">
                    <text>sigma (54)-gnAp2 is observed to be strongly inhibited by CRP-cAMP, by 21-folds.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="794">
                    <text>sigma (54)-gnAp2 was strongly inhibited by CRP-cAMP 21 times.</text>
                    <arg n="0">CRP-cAMP</arg>
                    <arg n="1">sigma (54)-gnAp2</arg>
                </example>
                <example src="PERMUTATE" no="795">
                    <text>the CRP-cAMP complex activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit the glnAp2 promoter activity.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="796">
                    <text>the CRP-cAMP complex also has the ability to inhibit the glnAp2 promoter activity in transient transfected T-cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="797">
                    <text>the CRP-cAMP complex can totally inhibit the glnAp2 promoter activity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="798">
                    <text>the CRP-cAMP complex inhibited the glnAp2 promoter activity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="799">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I (NO) activated the soluble isoform of cyclase guanilate in platelets and was observed to inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="800">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="801">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I (NO) inhibiting late clathrin-coated vesicle formation events activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="802">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I inhibited late clathrin-coated vesicles formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="803">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may also have inhibited late clathrin-coated vesicle formation events in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="804">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may also have inhibited late clathrin-coated vesicles formation events in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="805">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may have completely inhibited late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="806">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may have completely inhibited late clathrin-coated vesicle formation events which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="807">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I may have inhibited late clathrin-coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaffin I</arg>
                    <arg n="2">late clathrin-coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="808">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit late clathrin coated vesicles formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="809">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I also inhibited late clathrin coated vesicles formation events in transfected T-leukemia cells transfected.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="810">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I can totally inhibit late clathrin coated vesicles formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="811">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I has also inhibited late clathrin coated vesicles formation events in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="812">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibited late clathrin coated vesicles formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="813">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits late clathrin coated vesicles formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="814">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits late clathrin-coated vesicle formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="815">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I is able to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="816">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may have completely inhibited late clathrin coated vesicles formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin coated vesicles formation events</arg>
                </example>
                <example src="PERMUTATE" no="817">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I may have completely inhibited late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="PERMUTATE" no="818">
                    <text>the function or location of A1 would be inhibited if phosphatease is associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="819">
                    <text>the function or location of A1 would be inhibited if phosphatease were associated with other protein.</text>
                    <arg n="0">other protein</arg>
                    <arg n="1">phosphatease</arg>
                    <arg n="2">the function or location of A1</arg>
                </example>
                <example src="PERMUTATE" no="820">
                    <text>the glnAp2 promoter activity are inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="821">
                    <text>the glnAp2 promoter activity in T-lycemic cells transfected, wil is also inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="822">
                    <text>the glnAp2 promoter activity is a dependent and saturable concentration and has been totally inhibited with the CRP-cAMP complex, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="823">
                    <text>the glnAp2 promoter activity is a dependent and saturable concentration and was fully inhibited with the CRP-cAMP complex, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="824">
                    <text>the glnAp2 promoter activity was inhibited by the CRP-cAMP complex.</text>
                    <arg n="0">the CRP-cAMP complex</arg>
                    <arg n="2">the glnAp2 promoter activity</arg>
                </example>
                <example src="PERMUTATE" no="825">
                    <text>the regulation of phosphorylated state, state5 and state6 is able to be inhibited by a proteasome MG132 inhibitor and lactacitstin.</text>
                    <arg n="0">a proteasome MG132 inhibitor and lactacitstin</arg>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="826">
                    <text>the regulation of phosphorylated state, state5 and state6 is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">the regulation of phosphorylated state, state5 and state6</arg>
                </example>
                <example src="PERMUTATE" no="827">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 in T-lycemic cells transfected, wil is also inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="828">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is a dependent and saturable concentration and can be totally inhibited with inhibitors of the MG132 proteasome and lactacyttin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="829">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 is a dependent and saturable concentration and is observed to be totally inhibited with inhibitors of the MG132 proteasome and lactacyttin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="830">
                    <text>the regulation of the phosphorylated state, Stat5 and Stat6 was inhibited by inhibitors of the MG132 proteasome and lactacyttin.</text>
                    <arg n="0">inhibitors of the MG132 proteasome and lactacyttin</arg>
                    <arg n="2">the regulation of the phosphorylated state, Stat5 and Stat6</arg>
                </example>
                <example src="PERMUTATE" no="831">
                    <text>this synthetic peptide that binds to P may have inhibited its binding to C3b.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">its binding to C3b</arg>
                </example>
                <example src="REPLACE" no="1">
                    <text>10mM EDTA activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="2">
                    <text>10mM EDTA fully inhibiting concentration-dependent ligand and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="3">
                    <text>10mM EDTA inhibited ligand activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="4">
                    <text>10mM EDTA inhibited ligand activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="5">
                    <text>10mM EDTA inhibits ligand activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="6">
                    <text>A0 inhibited Lrp/PapI.</text>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="7">
                    <text>A0 inhibits intermediate events leading to the formation of clathrin coated wells.</text>
                    <arg n="2">intermediate events leading to the formation of clathrin coated wells</arg>
                </example>
                <example src="REPLACE" no="8">
                    <text>A0 inhibits intermediate events that lead to the formation of clathrin-coated paddocks.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="REPLACE" no="9">
                    <text>A0 is able to completely inhibit intermediate events that lead to the formation of clathrin-coated pins that is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="10">
                    <text>A0 is capable of completely inhibiting intermediate events that lead to the formation of clathrin-coated paddocks that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="REPLACE" no="11">
                    <text>A2 can be inhibited by 10mM EDTA that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="12">
                    <text>A2 can be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="13">
                    <text>A2 can be inhibited by This synthetic peptide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="14">
                    <text>A2 can be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="15">
                    <text>A2 can be inhibited by nails methylation that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="16">
                    <text>A2 can be inhibited by rolipram that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="17">
                    <text>A2 can be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="18">
                    <text>A2 can be inhibited by this synthetic peptide that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="19">
                    <text>A2 is capable of being inhibited by N-terminal SH3 domain that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="20">
                    <text>A2 is capable of being inhibited by protein extracts from transfect body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="21">
                    <text>A2 is inhibited by N-terminal domain H3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="22">
                    <text>A2 is inhibited by cell surface receptors for immunoglobulin and type C lectin that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="23">
                    <text>A2 is inhibited by methylation of prey that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                </example>
                <example src="REPLACE" no="24">
                    <text>A2 is inhibited by rolipram that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">rolipram</arg>
                </example>
                <example src="REPLACE" no="25">
                    <text>A2 may have been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="26">
                    <text>A2 may have been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="27">
                    <text>A2 may have been inhibited by protein extracts from transfected body cells that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="28">
                    <text>A2 will be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="29">
                    <text>A2 will be inhibited by cell surface receptors for immunoglobulin and lectin type C that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="30">
                    <text>A2 will be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="31">
                    <text>EDTA of 10 mM can fully inhibit binding that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="32">
                    <text>EDTA of 10 mM inhibited binding activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="33">
                    <text>EDTA of 10 mM may have completely inhibited binding that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="34">
                    <text>EDTA of 10 mM may have completely inhibited binding which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="35">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while 10mM EDTA inhibited ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="36">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain H3 inhibits intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="37">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain H3 is able to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="38">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while N-terminal domain SH3 may inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="39">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I is able to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="40">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and lectin type C inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="41">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and type C lectins superfamilies inhibits NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="42">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while cell surface receptors for immunoglobulin and type C lectins superfamilies may inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="43">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="44">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="45">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while late clathrin-coated vesicle formation events will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="46">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while ligand will be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="47">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while methylation of prey inhibited Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="48">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while methylation of prey may inhibit Lrp/PapI binding.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="49">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while methylation of snails inhibits Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="50">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while methylation of snails may inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="51">
                    <text>GadX activates the expression of gadA and gadBC at any pH, while the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I may have inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="52">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while 10mM EDTA inhibited ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="53">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while 10mM EDTA inhibits ligand.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="54">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while N-terminal domain H3 is observed to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="55">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while NK-mediated cytotoxicity is observed to be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="56">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin and lectin type C inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="57">
                    <text>GadX activates the expression of gadA and gadBC in any pH, while cell surface receptors for immunoglobulin and type C lectin inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="58">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10 mM EDTA can inhibit A2 promotional activity (gnAp2).</text>
                    <arg n="0">10 mM EDTA</arg>
                </example>
                <example src="REPLACE" no="59">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that 10mM EDTA inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="60">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM has inhibited binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="61">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM inhibited binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="62">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that EDTA of 10 mM inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">EDTA of 10 mM</arg>
                </example>
                <example src="REPLACE" no="63">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Lrp/PapI binding is inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="64">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Lrp/PapI connection is inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="65">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain has inhibited intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="66">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="67">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="68">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal SH3 domain will inhibited intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="69">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 has inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="70">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="71">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 will inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="72">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 can inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="73">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 has inhibited intermediate events that lead to the formation of a clathrin-coated well.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="74">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="75">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="76">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I can inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="77">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I has inhibited delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="78">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I has the ability to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="79">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I can inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="80">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="81">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="82">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I will inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="83">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that This synthetic peptide inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">This synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="84">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and lectin type C inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="85">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                </example>
                <example src="REPLACE" no="86">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies inhibited NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="87">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that crew methylation inhibited A2 promotional activity (gnAp2).</text>
                    <arg n="0">crew methylation</arg>
                </example>
                <example src="REPLACE" no="88">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late clathrin-coated vesicle formation events has been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="89">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="90">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand can be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="91">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that ligand will be inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="92">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of snails can inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="93">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that methylation of snails will inhibited Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="94">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nails methylation has the ability to inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="95">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that nails methylation will inhibited Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="96">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfect body cells inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="97">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that protein extracts from transfected body cells inhibited A2 activity (promocignAp2).</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="98">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="99">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="100">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I has inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="101">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I has the ability to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="102">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibits glnAp2 promotion activity (promotion complexgnAp2).</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="103">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I will inhibited late clathrin-coated vesicle formation events.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="104">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that this synthetic peptide inhibited A2 activity (promocignAp2).</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="105">
                    <text>Here, lets show that the expression glnAp2 is affected by different carbon sources and that this synthetic peptide inhibits A2 promotional activity (gnAp2).</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="106">
                    <text>Here, we have found that Lrp/PapI connection will be inhibited by methylation of snails, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="107">
                    <text>Here, we have found that NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectin, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="108">
                    <text>Here, we have found that intermediate events that lead to the formation of clathrin-coated pins has been inhibited by N-terminal domain H3, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="109">
                    <text>Here, we have found that intermediate events that lead to the formation of clathrin-coated wells has been inhibited by N-terminal SH3 domain, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="110">
                    <text>Here, we have found that intermediate events that lead to the formation of clathrin-coated wells will be inhibited by N-terminal SH3 domain, while phosphorylated state1 reabsorption, stat2 and stat3 are not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="111">
                    <text>Here, we have found that ligand is inhibited by 10mM EDTA, while phosphorylated state1 reabsorption, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="112">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that EDTA of 10 mM has the ability to inhibit binding.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="113">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that N-terminal SH3 domain is able to inhibit intermediate events that lead to the formation of clathrin-coated wells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="114">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that N-terminal domain H3 is able to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="115">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is able to be inhibited by cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="116">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that NK-mediated cytotoxicity is inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="117">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I is observed to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="118">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that binding will be inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="119">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="120">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that delayed clattrin-coated vesicles formation events will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="121">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that intermediate events that lead to the formation of clathrin-coated pins has been inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="122">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late clathrin-coated vesicle formation events is able to be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="123">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that late events of clathrin-coated vesicles formation will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="124">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that methylation of snails is able to inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="125">
                    <text>Here, we show that glnAp2 expression is affected by different carbon sources and that nails methylation has the ability to inhibit Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="126">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain H3 is observed to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="127">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that N-terminal domain SH3 inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="128">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibited late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="129">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I is observed to inhibit late clathrin-coated vesicle formation events.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="130">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectin is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="131">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that cell surface receptors for immunoglobulin and type C lectins superfamilies is observed to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="132">
                    <text>Here, we show that the expression glnAp2 is affected by different carbon sources and that methylation of snails is observed to inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="133">
                    <text>In this study, we found that binding will be inhibited by EDTA of 10 mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="134">
                    <text>In this study, we found that delayed clattrin-coated vesicles formation events will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="135">
                    <text>In this study, we found that intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain H3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="136">
                    <text>In this study, we found that intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain SH3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="137">
                    <text>In this work, we found that binding was inhibited by EDTA of 10 mM, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="138">
                    <text>In this work, we found that intermediate events that lead to the formation of clathrin-coated pins is inhibited by N-terminal domain SH3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="139">
                    <text>In this work, we found that intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain H3, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="140">
                    <text>In this work, we found that ligand was inhibited by 10mM EDTA, while the reabsorption of phosphorylated state1, stat2 and stat3 were not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="141">
                    <text>In this work, we found that ligand was inhibited by 10mM EDTA, while the reduced regulation of Stat1, Stat2 and Stat3 was not sensitive to these inhibitors.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="142">
                    <text>Lrp/PapI binding in transiently transfected Jurkat T-cells is also inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="143">
                    <text>Lrp/PapI binding is a dependent and saturable concentration and has been totally inhibited with methylation of prey, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="144">
                    <text>Lrp/PapI binding is a dependent and saturable concentration and is observed to be totally inhibited with methylation of prey, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="145">
                    <text>Lrp/PapI binding is able to be inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="146">
                    <text>Lrp/PapI binding is inhibited by methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="147">
                    <text>Lrp/PapI binding will be inhibited by methylation of prey which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="148">
                    <text>Lrp/PapI connection are inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="149">
                    <text>Lrp/PapI connection is a dependent and saturable concentration and has been totally inhibited with methylation of snails, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="150">
                    <text>Lrp/PapI connection is inhibited by methylation of snails which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="151">
                    <text>Lrp/PapI in transfectuously affected T-leukemia cells, wil is also inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="152">
                    <text>Lrp/PapI in transiently transfected Jurkat T-cells was also inhibited by nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="153">
                    <text>Lrp/PapI is a dependent and saturable concentration and can be fully inhibited with nails methylation, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="154">
                    <text>Lrp/PapI is a dependent and saturable concentration and has been totally inhibited with nails methylation, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="155">
                    <text>Lrp/PapI is a dependent and saturable concentration and is able to be fully inhibited with nails methylation, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="156">
                    <text>Lrp/PapI is a dependent and saturable concentration and was fully inhibited with nails methylation, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="157">
                    <text>N-terminal SH3 domain can totally inhibit intermediate events that lead to the formation of clathrin-coated wells that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="158">
                    <text>N-terminal SH3 domain has also inhibited intermediate events that lead to the formation of clathrin-coated wells in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="159">
                    <text>N-terminal SH3 domain inhibited intermediate events that lead to the formation of clathrin-coated wells activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="160">
                    <text>N-terminal SH3 domain may also have inhibited intermediate events that lead to the formation of clathrin-coated wells in T cells affected by jurkat.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="161">
                    <text>N-terminal domain H3 fully inhibiting concentration-dependent intermediate events that lead to the formation of clathrin-coated pins and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="162">
                    <text>N-terminal domain H3 inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">N-terminal domain H3</arg>
                </example>
                <example src="REPLACE" no="163">
                    <text>N-terminal domain H3 may also have inhibited intermediate events that lead to the formation of clathrin-coated pins in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="164">
                    <text>N-terminal domain SH3 (NO) inhibiting intermediate events that lead to the formation of clathrin-coated pins activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="165">
                    <text>N-terminal domain SH3 activates the soluble isoform of guanilate cyclase in platelets and has the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="166">
                    <text>N-terminal domain SH3 can fully inhibit intermediate events that lead to the formation of a clathrin-coated well that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="167">
                    <text>N-terminal domain SH3 has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="168">
                    <text>N-terminal domain SH3 inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="169">
                    <text>N-terminal domain SH3 inhibits intermediate events that lead to the formation of clathrin-coated pins activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="170">
                    <text>N-terminal domain SH3 may also have inhibited intermediate events that lead to the formation of clathrin-coated pins in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="171">
                    <text>N-terminal domain SH3 may have completely inhibited intermediate events that lead to the formation of a clathrin-coated well that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="172">
                    <text>N-terminal domain SH3 may have completely inhibited intermediate events that lead to the formation of clathrin-coated pins that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="173">
                    <text>N-terminal domain SH3 may have inhibited intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="174">
                    <text>NK-mediated cytotoxicity has been inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="175">
                    <text>NK-mediated cytotoxicity in T-lycemic cells transfected, wil is also inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="176">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and has been totally inhibited with cell surface receptors for immunoglobulin and type C lectin, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="177">
                    <text>NK-mediated cytotoxicity is a dependent and saturable concentration and is fully inhibited with cell surface receptors for immunoglobulin and type C lectin, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="178">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cell surface receptors for immunoglobulin and type C lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="179">
                    <text>NK-mediated cytotoxicity is capable of being inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="180">
                    <text>NK-mediated cytotoxicity was inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="181">
                    <text>NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectin which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="182">
                    <text>NK-mediated cytotoxicity will be inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="183">
                    <text>P is observed to be strongly inhibited by this synthetic peptide, by 21-folds.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="184">
                    <text>PDE4C is one of the four mammalian genes that codify P that can be inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="185">
                    <text>PDE4C is one of the four mammalian genes that codify both alpha and C beta isoforms of the catalytic subunit of PKA inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="186">
                    <text>PDE4C is one of the four mammalian genes that codify both alpha and C beta isoforms of the catalytic subunit of PKA that have been inhibited by protein extracts from transfected body cells.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="187">
                    <text>PDE4C is one of the four mammalian genes that codify cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="188">
                    <text>PDE4C is one of the four mammalian genes that codify multiple AMP-specific isoforms PDE4 and is inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="189">
                    <text>PDE4C is one of the four mammalian genes that codify multiple cyclic PDE4 AMP-specific isoform phosphodiesterase that can be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="190">
                    <text>Proteasome A0 inhibitors MG132 and lactacistin have the ability to inhibit intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="191">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="192">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I (NO) inhibiting delayed clattrin-coated vesicles formation events activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="193">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I also has the ability to inhibit delayed clattrin-coated vesicles formation events in transient transfected T-cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="194">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I also inhibited delayed clattrin-coated vesicles formation events in transfected T-leukemia cells transfected.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="195">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="196">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="197">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="198">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I (NO) inhibiting late events of clathrin-coated vesicles formation activated the soluble isoform of cyclose guanylate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="199">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I can inhibit late events of clathrin-coated vesicles formation.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="200">
                    <text>SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I inhibits late events of clathrin-coated vesicles formation activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="201">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I (NO) inhibiting late clathrin-coated vesicle formation events activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="202">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I also inhibited late clathrin-coated vesicle formation events in transfected T-leukemia cells transfected.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="203">
                    <text>Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I may have completely inhibited late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="204">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until A600 reached 0.3 and then Lrp/PapI was inhibited by 50 mg/ml nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="205">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then Lrp/PapI binding will be inhibited by 50 mg/ml methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="206">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="207">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity will be inhibited by 50 mg/ml cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="208">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then NK-mediated cytotoxicity will be inhibited by 50 mg/ml cell surface receptors for immunoglobulin and type C lectin.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="209">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins was inhibited by 50 mg/ml N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="210">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then intermediate events that lead to the formation of clathrin-coated pins will be inhibited by 50 mg/ml N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="211">
                    <text>The half-life of AGT proteins was determined by growing cells at 37 C in the LB embroidery complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then late clathrin-coated vesicle formation events will be inhibited by 50 mg/ml the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="212">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then binding will be inhibited by 50 mg/ml of EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="213">
                    <text>The half-life of AGT proteins was determined by growth of cells at 37 C in LB broth supplemented with 50 mg/ml of ampicillin, 50 mg/ml of cannamicin and 0.2 mM of IPTG until A600 has reached 0.3, then late clathrin-coated vesicle formation events will be inhibited by 50 mg/ml of Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="214">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml N-terminal domain SH3 to inhibiting intermediate events that lead to the formation of clathrin-coated pins.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="215">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I to inhibiting delayed clattrin-coated vesicles formation events.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="216">
                    <text>The half-life of AGT proteins was determined by the culture of cells at 37 C in the LB broth complemented by 50 mg/ml ampiciline, 50 mg/ml kanamicin and 0.2 mM IPTG until the A600 reached 0.3 and then treated them with 50 mg/ml nails methylation to inhibiting Lrp/PapI.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="217">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of cell surface receptors for immunoglobulin and lectin type C to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="218">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of cell surface receptors for immunoglobulin and type C lectin to inhibiting NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="219">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml ampicillin, 50 mg/ml calamicin and 0.2 mM of IPTG up to A600 reached 0.3 and then treated with 50 mg/ml of methylation of snails to inhibiting Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="220">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 had reached 0.3 and then late clathrin-coated vesicle formation events was inhibited by 50 mg/ml of Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="221">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then Lrp/PapI binding was about to be inhibited by 50 mg/ml of methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="222">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then Lrp/PapI binding was inhibited by 50 mg/ml of methylation of prey.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="223">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then Lrp/PapI is inhibited by 50 mg/ml of nails methylation.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="224">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then NK-mediated cytotoxicity was inhibited by 50 mg/ml of cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="225">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then delayed clattrin-coated vesicles formation events was inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="226">
                    <text>The half-life of AGT proteins was determined by the growth of cells at 37 C in the LB embroidery complemented by 50 mg/ml of ampicillin, 50 mg/ml of cannamycin and 0.2 mM of IPTG up to A600 reached 0.3 and then late events of clathrin-coated vesicles formation was inhibited by 50 mg/ml of SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="227">
                    <text>The intrigue is that, while the A0 domains (SH3C and SH3E intersectin, as well as the SH3 domains of endophyline endophyline I proteins, ampphisine II and symphpine I), they are observed to selectively inhibit intermediate events that lead to the formation of clathrin-coated wells involving membrane fission, the SH3A was only in its own domain</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="228">
                    <text>This synthetic peptide binding to P may have inhibited the binding to C3b.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                    <arg n="2">the binding to C3b</arg>
                </example>
                <example src="REPLACE" no="229">
                    <text>This synthetic peptide has the ability to strongly inhibit P by 21-folds.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="230">
                    <text>This synthetic peptide may have strongly inhibited P by 21-fold.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="231">
                    <text>Transient overexpression in body cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and multiple AMP-specific isoforms PDE4 are inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="232">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and protein extracts from transfected body cells is able to inhibit both alpha isoforms as C beta of the PKA catalytic subunit equally.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="233">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and rolipram is able to inhibit cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase equally.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="234">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and rolipram is able to inhibit multiple AMP-specific isoforms PDE4 equally.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="235">
                    <text>Transient overexpression in body cells has shown that a thermostable protein kinase inhibitor is produced by human DNA-PKI, and this synthetic peptide is able to inhibit P equally.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="236">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase has been produced by protein kinase PKI, and that This synthetic peptide could have inhibited P with equal effectiveness.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="237">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of protein kinase is produced by human DNA-PKI, and rolipram can inhibit cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="238">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that protein extracts from transfect body cells has inhibited both the C-alpha isoforms and the beta C of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="239">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase has been produced by the protein kinase PKI, and that rolipram has inhibited multiple cyclic PDE4 AMP-specific isoform phosphodiesterase with equal effectiveness.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="240">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that protein extracts from transfected body cells inhibits both alpha isoforms as C beta of the PKA catalytic subunit equally effectively.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="241">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that rolipram inhibits multiple AMP-specific isoforms PDE4 equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="242">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by human DNA-PKI, and it is observed that this synthetic peptide inhibits P equally effectively.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="243">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and both the C-alpha isoforms and the beta C of the catalytic subunit PKA are observed to be inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="244">
                    <text>Transient overexpression in body cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and multiple AMP-specific isoforms PDE4 are observed to be inhibited by rolipram.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="245">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="246">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by protein extracts from transfect body cells.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                </example>
                <example src="REPLACE" no="247">
                    <text>Transient overexpression in cells has shown that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by this synthetic peptide.</text>
                    <arg n="0">this synthetic peptide</arg>
                </example>
                <example src="REPLACE" no="248">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                </example>
                <example src="REPLACE" no="249">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="250">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human PKI cDNA, and that A1 isoforms (both C alpha and C beta of the catalytic subunit PKA) will be inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="251">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and This synthetic peptide can inhibit P with equal effectiveness.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="252">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and protein extracts from transfect body cells can inhibit both the C-alpha isoforms and the beta C of the catalytic subunit PKA with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="253">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and protein extracts from transfected body cells can inhibit both alpha isoforms as C beta of the PKA catalytic subunit with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="254">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that rolipram is capable of inhibiting cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="255">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that rolipram is capable of inhibiting multiple AMP-specific isoforms PDE4 equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="256">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase is produced by human mitochondrial DNA, and that rolipram is capable of inhibiting multiple cyclic PDE4 AMP-specific isoform phosphodiesterase equally effectively.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="257">
                    <text>Transient overexpression in cells has shown that a thermostable inhibitor of protein kinase was produced by human mitochondrial DNA, and that protein extracts from transfected body cells may have inhibited both alpha isoforms as C beta of the PKA catalytic subunit with equal effectiveness.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="258">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="259">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="260">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="261">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA are inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="262">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="263">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="264">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by cell surface receptors for immunoglobulin and type C lectins superfamilies.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                </example>
                <example src="REPLACE" no="265">
                    <text>Transient overexpression in cells showed that a thermo-stable protein kinase inhibitor is produced by the protein kinase of human PKI, and that the C alpha and C beta isoforms of the catalytic subunit PKA were inhibited by methylation of snails.</text>
                    <arg n="0">methylation of snails</arg>
                </example>
                <example src="REPLACE" no="266">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI cDNA, and P will be inhibited by This synthetic peptide.</text>
                    <arg n="0">This synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="267">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="268">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="269">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA are inhibited by cell surface receptors for immunoglobulin and lectin type C.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="270">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                </example>
                <example src="REPLACE" no="271">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                </example>
                <example src="REPLACE" no="272">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA have been inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphin I</arg>
                </example>
                <example src="REPLACE" no="273">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                </example>
                <example src="REPLACE" no="274">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                </example>
                <example src="REPLACE" no="275">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                </example>
                <example src="REPLACE" no="276">
                    <text>Transient overexpression in cells verified that a heat-stable inhibitor of the protein kinase is produced by the human PKI protein kinase, and that the isoforms C alpha and C beta of the catalytic subunit PKA were inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="277">
                    <text>binding in T cells of Jurkat transfects is also inhibited by EDTA of 10 mM.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="278">
                    <text>binding is a dependent and saturable concentration and is observed to be totally inhibited with EDTA of 10 mM, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">EDTA of 10 mM</arg>
                    <arg n="2">binding</arg>
                </example>
                <example src="REPLACE" no="279">
                    <text>both alpha isoforms as C beta of the PKA catalytic subunit is observed to be strongly inhibited by protein extracts from transfected body cells, by 21-folds.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="280">
                    <text>both the C-alpha isoforms and the beta C of the catalytic subunit PKA was strongly inhibited by protein extracts from transfect body cells 21 times.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="281">
                    <text>cell surface receptors for immunoglobulin and lectin type C has inhibited A1 (multiple PDE4-encoded PDE4C isoforms.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="282">
                    <text>cell surface receptors for immunoglobulin and lectin type C inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                </example>
                <example src="REPLACE" no="283">
                    <text>cell surface receptors for immunoglobulin and lectin type C inhibited NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="284">
                    <text>cell surface receptors for immunoglobulin and lectin type C inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="285">
                    <text>cell surface receptors for immunoglobulin and lectin type C inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="286">
                    <text>cell surface receptors for immunoglobulin and lectin type C may have completely inhibited NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and lectin type C</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="287">
                    <text>cell surface receptors for immunoglobulin and type C lectin (NO) inhibiting NK-mediated cytotoxicity activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="288">
                    <text>cell surface receptors for immunoglobulin and type C lectin also inhibits NK-mediated cytotoxicity in transiently transfected T-leukemia cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="289">
                    <text>cell surface receptors for immunoglobulin and type C lectin inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="290">
                    <text>cell surface receptors for immunoglobulin and type C lectin inhibits NK-mediated cytotoxicity activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="291">
                    <text>cell surface receptors for immunoglobulin and type C lectin may also have inhibited NK-mediated cytotoxicity in transfected T-cells transfected by jurkat.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="292">
                    <text>cell surface receptors for immunoglobulin and type C lectin may have completely inhibited NK-mediated cytotoxicity that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectin</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="293">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies also inhibited NK-mediated cytotoxicity in transfected T-leukemia cells transfected.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="294">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies fully inhibiting concentration-dependent NK-mediated cytotoxicity and is saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="295">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies is able to inhibit NK-mediated cytotoxicity.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="296">
                    <text>cell surface receptors for immunoglobulin and type C lectins superfamilies may have completely inhibited NK-mediated cytotoxicity which is concentration-dependent and saturable, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">cell surface receptors for immunoglobulin and type C lectins superfamilies</arg>
                    <arg n="2">NK-mediated cytotoxicity</arg>
                </example>
                <example src="REPLACE" no="297">
                    <text>cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase has been strongly inhibited by rolipram, by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="298">
                    <text>cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase is observed to be strongly inhibited by rolipram, by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">cyclic multiplicity PDE4 AMP-specific isoforms of phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="299">
                    <text>decreased regulation of Stat4, Stat5 and Stat6 phosphorylated are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">decreased regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="REPLACE" no="300">
                    <text>decreased regulation of Stat4, Stat5 and Stat6 phosphorylated were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">decreased regulation of Stat4, Stat5 and Stat6 phosphorylated</arg>
                </example>
                <example src="REPLACE" no="301">
                    <text>delayed clattrin-coated vesicles formation events in Jurkat T-leukemia transfect cells has also been inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="302">
                    <text>delayed clattrin-coated vesicles formation events in transiently transfected Jurkat T-cells was also inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="303">
                    <text>delayed clattrin-coated vesicles formation events is a dependent and saturable concentration and is fully inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="304">
                    <text>delayed clattrin-coated vesicles formation events is capable of being inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocrine proteins endophylin I, amphiphisin II and syndrophine I</arg>
                    <arg n="2">delayed clattrin-coated vesicles formation events</arg>
                </example>
                <example src="REPLACE" no="305">
                    <text>intermediate events that lead to the formation of a clathrin-coated well has been inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="306">
                    <text>intermediate events that lead to the formation of a clathrin-coated well in transiently transfected Jurkat T-cells was also inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="307">
                    <text>intermediate events that lead to the formation of a clathrin-coated well is a dependent and saturable concentration and is fully inhibited with N-terminal domain SH3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="308">
                    <text>intermediate events that lead to the formation of a clathrin-coated well was inhibited by N-terminal domain SH3 that activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of a clathrin-coated well</arg>
                </example>
                <example src="REPLACE" no="309">
                    <text>intermediate events that lead to the formation of clathrin-coated cubes were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated cubes</arg>
                </example>
                <example src="REPLACE" no="310">
                    <text>intermediate events that lead to the formation of clathrin-coated paddocks are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="REPLACE" no="311">
                    <text>intermediate events that lead to the formation of clathrin-coated paddocks were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated paddocks</arg>
                </example>
                <example src="REPLACE" no="312">
                    <text>intermediate events that lead to the formation of clathrin-coated pins are inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="313">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is a dependent and saturable concentration and is able to be fully inhibited with N-terminal domain SH3, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="314">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is able to be inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="315">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is capable of being inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="316">
                    <text>intermediate events that lead to the formation of clathrin-coated pins is observed to be inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="317">
                    <text>intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain H3.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="318">
                    <text>intermediate events that lead to the formation of clathrin-coated pins was inhibited by N-terminal domain SH3.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="319">
                    <text>intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain H3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain H3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="320">
                    <text>intermediate events that lead to the formation of clathrin-coated pins will be inhibited by N-terminal domain SH3 which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal domain SH3</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated pins</arg>
                </example>
                <example src="REPLACE" no="321">
                    <text>intermediate events that lead to the formation of clathrin-coated wells can be inhibited by N-terminal SH3 domain which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="322">
                    <text>intermediate events that lead to the formation of clathrin-coated wells in transfectuously affected T-leukemia cells, wil is also inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="323">
                    <text>intermediate events that lead to the formation of clathrin-coated wells in transiently transfected Jurkat T-cells is also inhibited by N-terminal SH3 domain.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="324">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is a dependent and saturable concentration and can be fully inhibited with N-terminal SH3 domain, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="325">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is capable of being inhibited by N-terminal SH3 domain which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="326">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is concentration-dependent and saturable and is able to be fully inhibited with N-terminal SH3 domain , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="327">
                    <text>intermediate events that lead to the formation of clathrin-coated wells is inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphisin I.</text>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="328">
                    <text>intermediate events that lead to the formation of clathrin-coated wells may have been inhibited by N-terminal SH3 domain which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">N-terminal SH3 domain</arg>
                    <arg n="2">intermediate events that lead to the formation of clathrin-coated wells</arg>
                </example>
                <example src="REPLACE" no="329">
                    <text>late clathrin-coated vesicle formation events is a dependent and saturable concentration and can be totally inhibited with the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="330">
                    <text>late clathrin-coated vesicle formation events is capable of being inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="331">
                    <text>late clathrin-coated vesicle formation events is concentration-dependent and saturable and is able to be fully inhibited with Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I , suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="332">
                    <text>late clathrin-coated vesicle formation events is inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="333">
                    <text>late clathrin-coated vesicle formation events is inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="334">
                    <text>late clathrin-coated vesicle formation events is observed to be inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="335">
                    <text>late clathrin-coated vesicle formation events was inhibited by Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I.</text>
                    <arg n="0">Sh3C and J3E domains of intersectin, as well as the SH3 domains of endocile proteins endophyline I, amphiphisine II and symphpine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="336">
                    <text>late clathrin-coated vesicle formation events was inhibited by the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="337">
                    <text>late clathrin-coated vesicle formation events were inhibited by A0 (SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I.</text>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="338">
                    <text>late events of clathrin-coated vesicles formation can be inhibited by SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="339">
                    <text>late events of clathrin-coated vesicles formation is a dependent and saturable concentration and can be totally inhibited with SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">SH3C and SH3E domains of intersectin, as well as SH3 domains of endocytic proteins endophylin I, amphiphisin II and symphiphine I</arg>
                    <arg n="2">late events of clathrin-coated vesicles formation</arg>
                </example>
                <example src="REPLACE" no="340">
                    <text>ligand is a dependent and saturable concentration and is able to be fully inhibited with 10mM EDTA, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="341">
                    <text>ligand is a dependent and saturable concentration and was fully inhibited with 10mM EDTA, suggesting that different cations were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="342">
                    <text>ligand is inhibited by 10mM EDTA which activates the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="343">
                    <text>ligand is inhibited by 10mM EDTA.</text>
                    <arg n="0">10mM EDTA</arg>
                    <arg n="2">ligand</arg>
                </example>
                <example src="REPLACE" no="344">
                    <text>methylation of prey co-expression also has the ability to inhibit Lrp/PapI binding in T-leukemia transnetly affected cells.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="345">
                    <text>methylation of prey may also have inhibited Lrp/PapI binding in T cells affected by jurkat.</text>
                    <arg n="0">methylation of prey</arg>
                    <arg n="2">Lrp/PapI binding</arg>
                </example>
                <example src="REPLACE" no="346">
                    <text>methylation of snails (NO) activates the soluble isoform of guanylate cyclase in platelets and has the ability to inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="347">
                    <text>methylation of snails (NO) inhibiting Lrp/PapI connection activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="348">
                    <text>methylation of snails can totally inhibit Lrp/PapI connection that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="349">
                    <text>methylation of snails has also inhibited Lrp/PapI connection in Jurkat trans-netentially transfected T-leukemia cells.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="350">
                    <text>methylation of snails is able to inhibit Lrp/PapI connection.</text>
                    <arg n="0">methylation of snails</arg>
                    <arg n="2">Lrp/PapI connection</arg>
                </example>
                <example src="REPLACE" no="351">
                    <text>multiple cyclic PDE4 AMP-specific isoform phosphodiesterase was strongly inhibited by rolipram 21 times.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="352">
                    <text>nails methylation can fully inhibit Lrp/PapI that is concentration-dependent and saturable, suggesting that different cationes were needed for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="353">
                    <text>nails methylation can totally inhibit Lrp/PapI that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="354">
                    <text>nails methylation inhibit the soluble isoform of cyclase guanilate in platelets and A2 inhibition (platquet function) has been observed.</text>
                    <arg n="0">nails methylation</arg>
                </example>
                <example src="REPLACE" no="355">
                    <text>nails methylation inhibited Lrp/PapI activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">nails methylation</arg>
                    <arg n="2">Lrp/PapI</arg>
                </example>
                <example src="REPLACE" no="356">
                    <text>protein extracts from transfect body cells is able to inhibit both the C-alpha isoforms and the beta C of the catalytic subunit PKA.</text>
                    <arg n="0">protein extracts from transfect body cells</arg>
                    <arg n="1">both the C-alpha isoforms and the beta C of the catalytic subunit PKA</arg>
                </example>
                <example src="REPLACE" no="357">
                    <text>protein extracts from transfected body cells inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                </example>
                <example src="REPLACE" no="358">
                    <text>protein extracts from transfected body cells is able to inhibit both alpha and C beta isoforms of the catalytic subunit of PKA.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="359">
                    <text>protein extracts from transfected body cells is able to inhibit both alpha isoforms as C beta of the PKA catalytic subunit.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha isoforms as C beta of the PKA catalytic subunit</arg>
                </example>
                <example src="REPLACE" no="360">
                    <text>protein extracts from transfected body cells is able to strongly inhibit both alpha and C beta isoforms of the catalytic subunit of PKA by 21-fold.</text>
                    <arg n="0">protein extracts from transfected body cells</arg>
                    <arg n="1">both alpha and C beta isoforms of the catalytic subunit of PKA</arg>
                </example>
                <example src="REPLACE" no="361">
                    <text>rolipram can strongly inhibit multiple AMP-specific isoforms PDE4 by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="362">
                    <text>rolipram has the ability to inhibit phosphorylase-specific multiple AMP-specific isoforms PDE4-isoforms coded by PDE4C.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="363">
                    <text>rolipram has the ability to strongly inhibit multiple cyclic PDE4 AMP-specific isoform phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="364">
                    <text>rolipram has the ability to strongly inhibit multiple cyclic PDE4 AMP-specific isoform phosphodiesterase by 21-folds.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="365">
                    <text>rolipram is able to inhibit multiple AMP-specific isoforms PDE4.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple AMP-specific isoforms PDE4</arg>
                </example>
                <example src="REPLACE" no="366">
                    <text>rolipram strongly inhibited multiple cyclic PDE4 AMP-specific isoform phosphodiesterase by 21-fold.</text>
                    <arg n="0">rolipram</arg>
                    <arg n="1">multiple cyclic PDE4 AMP-specific isoform phosphodiesterase</arg>
                </example>
                <example src="REPLACE" no="367">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I (NO) inhibiting late clathrin-coated vesicle formation events activated the soluble isoform of guanylate cyclase in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="368">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I also has the ability to inhibit late clathrin-coated vesicle formation events in transient transfected T-cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="369">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I also inhibits late clathrin-coated vesicle formation events in transiently transfected T-leukemia cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="370">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I can totally inhibit late clathrin-coated vesicle formation events that is concentration-dependent and saturable, suggesting that divalent cations were necessary for the interaction of IN1B with Vero cells.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="371">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibited late clathrin-coated vesicle formation events activates the soluble isoform of cyclase guanilate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="372">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibited late clathrin-coated vesicle formation events activates the soluble isoform of cyclosis guanylate in platelets.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                    <arg n="2">late clathrin-coated vesicle formation events</arg>
                </example>
                <example src="REPLACE" no="373">
                    <text>the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I inhibited the phosphodiesterase-specific multiple PDE4 isoforms coded by PDE4C.</text>
                    <arg n="0">the SH3C and SH3E domains of the intersectin, as well as the SH3 domains of endocile proteins endophilin I, amphifisin II and sindaphine I</arg>
                </example>
                <example src="REPLACE" no="374">
                    <text>this synthetic peptide has the ability to strongly inhibit P by 21-fold.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="375">
                    <text>this synthetic peptide inhibits P codified by PDE4C.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
                <example src="REPLACE" no="376">
                    <text>this synthetic peptide is able to inhibit P coded by PDE4C.</text>
                    <arg n="0">this synthetic peptide</arg>
                    <arg n="1">P</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
